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SUMMARY 
Most vaccines are currently administered by healthcare personnel using a needle 
and syringe. This delivery method poses significant hurdles in vaccine delivery, 
especially in developing countries. We propose dissolving microneedle patches to be a 
suitable alternative to needle and syringe vaccination in developing countries. Dissolving 
microneedle patches contain micron sized needles made out of water-soluble 
biodegradable polymers that dissolve in the skin to deliver the vaccine. They offer the 
simplicity of patch application and the possibility to mitigate the logistical and safety 
challenges associated with conventional hypodermic needles.  
The overall goal of this thesis was to develop dissolving microneedle patches to 
further clinical translation of this technology in the context of vaccinations in developing 
countries. We studied two specific scenarios, development of microneedle patches for 
rabies vaccination of dogs and assessment of dissolving microneedle patches in human 
subjects. Human rabies is eliminated in most developed countries by employing control 
measures of vaccinations in animals. However, dogs account for nearly all human rabies 
infections in developing countries and vaccinations are difficult to employ in animals due 
to the need of a needle and syringe and the cost of administration. While microneedle 
patches are in pre-clinical development for different vaccines, limited information is 
available about their use in human subjects, which will be important for clinical 
translation.  
The central hypothesis was that rabies vaccine can be stabilized in a dissolving 
microneedle patch and be at least as immunogenic as conventional needle and syringe 
while enabling simple administration and that dissolving microneedle patches could be 
 xix
easily administered without the need of an applicator, be well tolerated in the skin and 
preferred over needle and syringe administration. This was assessed by engineering 
patches for veterinary rabies vaccination and evaluating immune response in dogs and 
determining tolerability, usability and acceptability of placebo microneedle patches in 
human subjects.  
The first study reports on rabies vaccination in dogs using a dissolving 
microneedle patch to enable simple and reliable intradermal rabies vaccination of dogs. 
The results show that the vaccine was stable upon formulation and storage for at least 3 
weeks at 4 °C in a microneedle patch. Microneedle patches were well tolerated in the 
skin, with mild erythema, minimal wheal formation and complete resolution of skin 
reactions within 7 days, and generated no systemic adverse events. Microneedle patches 
were at least as immunogenic as intramuscular injection at the same dose, as 
demonstrated by similar serum neutralizing antibody titers. A ten-fold lower vaccine dose 
administered by microneedle patch generated a weaker immune response compared to 
full-dose intramuscular vaccination. 
The second study reports on tolerability, usability and acceptability of dissolving 
microneedle patch administration in human subjects without the use of an applicator. The 
results show that microneedle patches were very well tolerated in the skin with minimal 
erythema that resolved fully within seven days and caused no pain or swelling. 
Microneedle patches were administered reliably by hand without the need of an 
applicator and delivery efficiencies were similar between investigator-administration and 
self-administration. Microneedle patch administration was not painful and the large 
majority of subjects were at least somewhat confident that they self-administered the 
 xx
patch correctly. Microneedle patch administration was overwhelmingly preferred over 
conventional needle and syringe injection for delivery of medications. 
Altogether, the positive results from these studies should further clinical 
translation of microneedles in the context of vaccination in developing countries. 
 
1 
CHAPTER 1 
INTRODUCTION  
 
1.1 Motivation 
 Vaccination is one of the most effective ways to reduce morbidity and mortality 
associated with vaccine-preventable diseases [1]. Most vaccines are currently 
administered by healthcare personnel using a needle and syringe. This delivery method 
poses significant hurdles in vaccine delivery, especially in developing countries. It 
requires trained personnel to administer each dose, creates medical sharps waste that 
must be safely disposed of to prevent reuse and necessitates the need of cold chain for 
vaccine stability [2, 3]. Dissolving microneedle patches contain micron-sized needles 
made out of water-soluble biodegradable polymers that dissolve in the skin to deliver the 
vaccine [4-6]. They offer the simplicity of patch application and the possibility to 
mitigate the logistical and safety challenges associated with conventional hypodermic 
needles.  
 Human rabies is eliminated in most developed countries by employing control 
measures of vaccinations in animals [7]. Dogs account for transmission of nearly all 
human rabies infections in developing countries [8] and vaccinations are difficult to 
employ in animals due to the need of a needle and syringe and the cost of administration 
[9]. We propose that dissolving microneedle patches can be a substitute to needle and 
syringe injection this vaccination scenario.  
 Dissolving microneedle patches have previously been studied for delivery of other 
drugs and vaccines in pre-clinical models, but limited information is available about 
 2 
clinical administration of microneedle patches [4, 5, 10-16]. As microneedle patches 
continue to be developed for delivery of vaccines, it will also be important to characterize 
their use in human subjects. We therefore propose to evaluate dissolving microneedle 
patches in human subjects to understand the reactions in the skin after administration and 
dissolution of microneedles as well as the efficiency of microneedle delivery. 
 
1.2 Specific aims 
The overall goal of this thesis is to develop dissolving microneedle patches to 
further clinical translation in the context of vaccination in developing countries. The 
overall hypothesis is that rabies vaccine can be stabilized in a dissolving microneedle 
patch and be at-least as immunogenic as needle and syringe injection while enabling 
simple administration. To study this hypothesis, we investigated the following specific 
aims: 
Aim 1: Engineer dissolving microneedle patches for rabies vaccination and evaluate 
immunogenicity and dose sparing in dogs. 
We hypothesize that rabies DNA vaccine can be suitably stabilized in a dissolving 
microneedle patch, and that the patches can be reliably and easily inserted into dog ears, 
are safe and well tolerated and are at least as immunogenic as intramuscular injection in 
Beagle dogs. 
Aim 2: Evaluate tolerability, usability and acceptability of dissolving microneedle 
patch administration in human subjects. 
We hypothesize that a controlled-bioburden process can be developed to fabricate 
dissolving microneedle patches suitable for use in humans and that microneedle patches 
 3 
can be inserted into skin by forces generated with the thumb without the need for an 
applicator. After insertion and dissolution, we hypothesize that the microneedles are 
well-tolerated in the skin and preferred over conventional hypodermic needles for 
delivery of vaccines.  
 
1.3 Outline of remaining chapters 
Chapter 2 contains background information on the polio and rabies vaccine 
delivery challenges and clinical translation of microneedle patches. Chapter 3 contains a 
review on microneedle patches for vaccination in developing countries. Chapters 4 - 6 
contain work done on the specific aims. Chapter 7 contains the key conclusions and 
Chapter 8 provides recommendations and future work.  
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CHAPTER 2 
BACKGROUND  
 
2.1 Rabies vaccination 
2.1.1 Rabies virus and disease 
Rabies virus is a RNA virus shaped like a bullet, 200 nm long and 75 nm wide. 
The virus contains multiple copies of the five structural proteins – virion transcriptase 
(L), glycoprotein (G), nucleoprotein (N), phosphoprotein (P) and matrix protein (M) [1]. 
The rabies virus G protein is the major antigen responsible for production of virus 
neutralizing antibodies and for conferring immunity against lethal infection with rabies 
[2].  
Rabies is an acute, often fatal encephalitis caused by viruses in the Rhabdoviridae 
family [3]. The disease is zoonotic and human infection usually results from a bite or 
scratch from an infected animal or direct contact of skin wounds with virus-containing 
saliva. After a bite, the virus in saliva attaches to the nerve endings and travels to the 
brain. Once the virus reaches the central nervous system and symptoms begin to show, 
the disease is almost always fatal. Rarely infections due to inhalation of the virus, 
inoculations with improperly inactivated vaccine or through transplantation of infected 
corneas, tissues and organs have been reported [3]. Although all warm-blooded animals 
can be reservoirs of rabies, dogs account for 99% of human deaths due to rabies and pose 
a potential threat to more than 3.3 billion people [4]. Globally, an estimated 26,000 to 
61,000 deaths are caused by rabies each year, more than 95% of which occur in Africa 
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and Asia due to dog bites [5]. Rabies occurs mainly in remote rural communities where 
children between the age of 5–14 years are the most frequent victims [6]. Human rabies 
has been almost eliminated in industrialized countries by widespread and often 
mandatory vaccination of dogs and other animals, as well as the availability of vaccines 
for humans [5]. 
2.1.2 Vaccination in humans 
Since their development many decades ago, concentrated, purified cell culture and 
embryonated egg-based vaccines have proved to be safe and effective in preventing 
rabies [5]. These vaccines are given for both pre-exposure and post-exposure 
prophylaxis. Humans are not typically vaccinated for rabies prevention but pre-exposure 
prophylaxis is recommended for anyone who will be at continual, frequent or increased 
risk of exposure to the rabies virus. Laboratory workers, veterinarians, animal handlers 
and travelers at high risk are recommended. An older vaccine derived from animal nerve 
tissues is no longer recommended for use in people because they have a higher number of 
adverse events and are less immunogenic than cell culture vaccines [5]. Upon exposure, it 
is recommended that the wound be thoroughly cleaned with soap and water, and the 
rabies vaccine be administered [7]. Rabies immunoglobulin is also administered once and 
multiple booster shots of the vaccine are given [8]. The vaccines are usually given 
intramuscularly, but in some countries are approved to be given at a low-dose via the 
intradermal route [9]. Intradermal vaccination using one-fifth to one-tenth the dose of 
rabies vaccine has been shown to be effective in humans, thereby enabling significant 
cost savings [4, 10-12]. 
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2.1.3 Vaccination in animals 
Veterinary vaccines have been developed for use against rabies in domestic 
mammals and wildlife. Injectable live virus vaccines are no longer used in domestic 
animals due to their inherent ability to cause rabies [4]. An injectable live recombinant 
vectored vaccine is available for use in cats in the US. The most widely used vaccines 
worldwide are injectable inactivated vaccines because they are safe and inexpensive. 
There is only one oral rabies vaccine approved for use in dogs but its use has been limited 
when vaccinating dogs because the bait in which the vaccine is contained does not always 
lead to complete delivery of vaccine and in developing countries where the contact with 
street dogs is high the use of oral vaccines is usually limited to areas with minimal human 
activity so as to ensure safe distribution [5]. Limited vaccination of dogs and availability 
of post exposure prophylaxis for people is the cause of most of the deaths due to rabies in 
developing countries. The WHO recommends mass vaccination of at least 70% of the 
dog population to control canine rabies in endemic areas [5].  
Different rabies DNA vaccines are currently being studied for vaccination of dogs 
and other animals and their efficacy has been shown in companion animals [13-15]. DNA 
vaccines could be much less costly to manufacture compared to inactivated virus 
vaccines like the conventional rabies vaccine for human vaccination [16, 17]. This is 
because DNA vaccines can be produced in large quantities by bacterial fermentation 
processes and may not require expensive facilities with high biosafety levels for 
production [18]. DNA vaccines could also show stability at high temperatures reducing 
the need for cold chain [17]. 
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Currently, there are a few DNA-based products approved for animal use. West 
Nile virus vaccine for horses, infectious hematopoietic necrosis virus vaccine for salmon 
fish, canine melanoma vaccine for dogs and a growth hormone releasing hormone gene 
therapy product for swine and food animals [16]. These licensures are important 
validations of the DNA vaccine platform and illustrate its commercial potential. It shows 
that DNA vaccines can be manufactured to scale and at low cost and that large animals 
can be successfully protected by specific DNA approaches. In addition, the generic nature 
of production and purification of plasmid vaccines can enable tech transfer to developing 
countries and low cost of vaccines [17].  
 
2.2 Microneedles 
 Microneedles are micron-sized needles up to 1 mm in length which are able to 
minimally penetrate past the biological barrier membranes for targeted drug delivery 
[19]. Microneedles are being studied for drug delivery to the skin by penetrating the 
stratum corneum [20], drug delivery to the back of the eye by penetrating the sclera [21] 
and drug delivery to cells by penetrating the cell membrane [22]. In the case of drug 
delivery to the skin, microneedles are able to penetrate the skin’s protective physical 
layer called the stratum corneum, which is about 20 µm thick [23]. It has been shown that 
by penetrating this upper most layer of skin, drug delivery to the skin can be increased by 
orders of magnitude [20].  
 Microneedles are generally of the following four types – solid microneedles, 
coated microneedle patch, dissolving microneedle patch and hollow microneedles. Figure 
2.1 shows the delivery mechanism of each of the microneedle types [24]. This thesis 
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project covers microneedle patches for drug or vaccine delivery. Chapter 3 discusses 
background regarding microneedle patches and their advantages specific to vaccine 
delivery in developing countries. 
  
Fig 2.1 Methods of drug delivery to the skin using microneedles (MN). Microneedles are 
first applied to the skin (A) and then used for drug delivery (B). Solid microneedles are 
used as a pretreatment, after which drug can diffuse through residual holes in skin from a 
topical formulation (solid MN). After insertion of drug-coated microneedles into the skin, 
the drug coating dissolves off the microneedles in the aqueous environment of the skin 
(coated MN). Drug-loaded microneedles are made of water-soluble or biodegradable 
materials encapsulating drug that is released in the skin upon microneedle dissolution 
(dissolving MN). Hollow microneedles are used to inject liquid formulations into the skin 
(hollow MN) [24]. 
 
2.2.1 Dissolving microneedle patches 
 Dissolving microneedle patches are made up of water soluble biocompatible or 
biodegradable polymers and sugars and the drug or vaccine is contained within the needle 
such that when the microneedle patch is applied to the skin, the microneedles dissolve in 
the skin and deliver the payload contained within them. After insertion and dissolution 
into the skin, dissolving microneedle patches do not leave behind any sharps waste. They 
offer the key advantage of minimizing the possibility of needle stick injury to healthcare 
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provider and do not require safe disposal of biohazardous sharps waste after drug or 
vaccine delivery [25]. 
 
Fig 2.2 Dissolving polymer microneedle patches. (A) Side view of dissolving polymer 
microneedles. (B) Relative height of an array of microneedles next to a US nickel coin. 
(C) En face view of porcine cadaver skin after insertion and removal of microneedles, 
showing delivery of the encapsulated compound (sulforhodamine) [26].  
 Different materials have been used in the formulation of dissolving microneedle 
patches resulting in dissolution times ranging from few minutes to hours, varying 
microneedle strengths and varying stability of the encapsulated antigen. Dissolving 
microneedle patches have been studied for delivery of different antigens – for example, 
Adenovirus [27-30], Amyloid β peptide [31], Diphtheria [32-36], HIV [37], Influenza 
[35, 38-64], Malaria [29, 32, 65], Measles [66], Poliovirus [67], Tetanus [32].  
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CHAPTER 3 
MICRONEEDLE PATCHES FOR VACCINATION IN 
DEVELOPING COUNTRIES 
 
Reprinted (adapted) with permission from Elsevier (Jaya Arya, Mark R. Prausnitz, 
Microneedle patches for vaccination in developing countries, Journal of Controlled 
Release).  
3.1 Abstract 
Millions of people die of infectious diseases each year, mostly in developing 
countries, which could largely be prevented by the use of vaccines. While immunization 
rates have risen since the introduction of the Expanded Program on Immunization (EPI), 
there remain major challenges to more effective vaccination in developing countries. As a 
possible solution, microneedle patches containing an array of micron-sized needles on an 
adhesive backing have been developed to be used for vaccine delivery to the skin. These 
microneedle patches can be easily and painlessly applied by pressing against the skin and, 
in some designs, do not leave behind sharps waste. The patches are single-dose, do not 
require reconstitution, are easy to administer, have reduced size to simplify storage, 
transportation and waste disposal, and offer the possibility of improved vaccine 
immunogenicity, dose sparing and thermostability. This review summarizes vaccination 
challenges in developing countries and discusses advantages that microneedle patches 
offer for vaccination to address these challenges. We conclude that microneedle patches 
offer a powerful new technology that can enable more effective vaccination in developing 
countries.  
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3.2 Barriers to vaccination in developing countries 
According to 2014 WHO estimates, 1.5 million children die each year from vaccine-
preventable diseases for which there are vaccines recommended by the WHO and 29% of 
deaths among children 1-59 months old are vaccine preventable [1]. For example, 
measles vaccine is 97% effective after two doses [2], yet, as of 2010, more than 100,000 
children under the age of five died each year from measles, most of whom were 
unvaccinated children [3].  
Vaccines are currently administered in developing countries primarily in two 
scenarios: routine vaccination and mass vaccination campaigns. Routine vaccination is 
used to achieve high immunization coverage on an on-going basis, but can fall short by 
itself due to infrastructural challenges in developing countries. Instead, or in addition, 
mass vaccination campaigns are employed to target large populations in specific regions 
more effectively [4, 5]. Mass vaccination campaigns can be performed at fixed-post 
clinics, which is typically required for injectable vaccines, or can be carried out door-to-
door, usually by minimally trained personnel administering non-injectable vaccines [6].  
While immunization rates have risen since the introduction of the Expanded Program 
on Immunization (EPI), there remain significant barriers to more effective vaccination in 
developing countries (Table 3.1). We summarize these barriers in the rest of this section.  
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Table 3.1. Barriers to more effective vaccination in developing countries. 
Barriers to more effective vaccination in developing countries [7, 8] 
Need for increased vaccine effectiveness 
Need for trained healthcare providers  
Need for effective supply chain 
Risk of sharps 
Vaccine wastage due to multi-dose vials 
Need for vaccine reconstitution  
Cost of vaccine/vaccination 
 
3.2.1 Need for increased vaccine effectiveness  
While many vaccines are extremely effective and offer life-long protection, other 
vaccines provide only moderate protection rates, especially in developing countries 
where nutrition levels may be low and individuals may have a compromised immune 
system due to presence of other infections [9, 10]. Most vaccines need booster doses in 
order to mount an appropriate immune response; this requires vaccinating the same 
people multiple times, which can be difficult to execute in places with poor healthcare 
infrastructure and recordkeeping. 
 For example, the efficacy of oral polio vaccine (OPV) is known to be sub-optimal 
in densely populated tropical countries [9] and the immunogenicity of rotavirus vaccine 
has been shown to be much worse in resource-poor countries in Africa and Asia [11-13]. 
Measles vaccine can be less efficacious in the presence of vitamin A deficiency in 
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developing countries and vitamin A supplementation along with measles vaccination is 
often recommended [10]. 
 
3.2.2 Need for trained healthcare providers 
Most vaccines are administered by hypodermic needle and syringe injection. A 
trained healthcare provider is needed to safely administer these injections as well as to 
safely dispose of the resulting sharps waste. The lack of trained healthcare providers in 
developing countries can be a significant barrier to attaining high vaccination rates, 
especially in the case of vaccination campaigns [14].  
 Smallpox eradication was achieved in part due to the ability to achieve high 
vaccination coverage using minimally trained personnel administering the vaccine using 
the scarification technique with a bifurcated needle [15]. Similarly, OPV is being 
administered orally by minimally  trained personnel as part of polio eradication efforts 
[14], and the anticipated switch to inactivated polio vaccine (IPV) that is given by 
injection is of great concern to public health officials due to its increased cost and 
complexity [16] .  
 
3.2.3 Need for effective supply chain  
Vaccines must be maintained at the correct temperature (i.e., usually refrigerated) 
during storage and distribution as well as during use after reconstitution. Heat and 
freezing temperatures are both detrimental to most vaccines. The resulting need for a cold 
chain during storage and distribution can be difficult to maintain due to limited 
infrastructure in developing countries, leading to vaccine wastage [17, 18]. Size and 
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volume of vaccine vials and syringes are thus also important considerations to utilize the 
supply chain most effectively [19, 20]. 
 The cost of the cold chain is estimated to be $200 to $300 million per year [18] 
and can even experience failures in industrialized countries with established cold chain 
systems [17], indicating that developing countries with less-established cold chain 
systems can be especially susceptible to losses in the cold chain.. As an example of the 
variation in cold-chain space occupied by a given vaccine presentation, estimates suggest 
that one dose of a given vaccine in a  10-dose vial occupies 3 cm3 of cold-chain volume, 
where as one dose of vaccine in a single-dose vial presentation occupies 12.9 cm3 of 
cold-chain volume [21].  
 
3.2.4 Risk of sharps  
Hypodermic needles need to be handled carefully to prevent needle-stick injuries 
to healthcare providers and others. Hypodermic needles also create biohazardous sharps 
waste after use that needs to be disposed of safely to ensure that the needles are not 
reused intentionally or accidentally. During vaccination campaigns it may be more 
difficult to safely collect and dispose of needles in developing countries [22, 23] 
 Both healthcare workers and patients are at risk due to unsafe injection practices. 
A study estimated that up to 33,800 HIV infections, 1.7 million hepatitis B infections and 
315,000 hepatitis C infections are caused every year due to unsafe injection practices 
[24]. 
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3.2.5 Vaccine wastage due to multi-dose vials 
Many vaccines are available in multi-dose (e.g., ten-dose) vials for injection. On a 
per-dose basis, multi-dose vials are less expensive than single dose vials, take up less 
space during transportation and in the cold-chain and create less waste. However, the 
actual cost savings can be difficult to evaluate based on the amount of vaccine that gets 
wasted because opened vials need to be used quickly to prevent microbial growth and, if 
not used in time, must be discarded. Vaccine wastage can be very high in developing 
countries for some vaccines [25-27].  
 In general vaccine wastage rates increase as the number of vaccine doses per vial 
increases and an estimate suggests wastage rates for 10 dose vials could be as high as 
25% for liquid vaccines and 40% for lyophilized vaccines [21]. The WHO Vaccine 
Presentation and Packaging Advisory Group’s guidelines recommend vaccines to be 
presented in formats to minimize the number of steps and potential for error during 
administration when possible [20]. 
 
3.2.6 Need for vaccine reconstitution 
Some vaccines are lyophilized and need to be reconstituted with a diluent at the 
time of use for injection, which adds additional challenges in developing countries [28]. 
Reconstitution adds another step that requires additional reconstitution needles, syringes 
and vials that also need to be stored and transported in part in the cold chain, further 
complicating the supply chain. Time and expertise is needed to reconstitute the vaccine 
since there is room for error if an incorrect diluent is used or mixing is not carried out 
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using sterile devices. Reconstitution errors lead to vaccine wastage, ineffective 
vaccination or, in some cases, injury to patients.  
 As an example, measles vaccine contamination by Staphylococcus Aureus from 
non-sterile diluent has been documented in many countries and accidental injection of 
other drugs stored in the diluent’s container have resulted in infant deaths [28]. In a 
recent case in Syria, the use of an incorrect diluent for the reconstitution of measles 
vaccine caused the death of 15 children [24]. 
 
3.2.7 Cost of vaccine/vaccination 
The cost of vaccination is the cost of vaccine plus the logistical costs associated 
with making the vaccine available for use. Healthcare provider, waste disposal, vaccine 
transportation, cold-chain and vaccine wastage all contribute to the cost of vaccination  
[29, 30]. While vaccine manufacturers often sell vaccine at significantly reduced cost for 
use in developing countries, the logistical costs to vaccinate can remain a significant 
barrier.  
As evidence of the significance of vaccination costs other than the cost of the 
vaccine itself, a study of the average cost to administer vaccines in Senegal found that 
logistics comprise approximately 50% of the total average cost of each dose delivered 
[29]. As another example, the 2015 UNICEF price for measles/rubella vaccine is 
US$0.578 per dose [31], but the cost to administer a dose of measles and rubella vaccine 
is estimated at approximately US$1.50 per dose [32].  
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3.3 Microneedle patches address challenges to vaccination in developing countries 
3.3.1 Overview of microneedles for vaccination 
Microneedle patches (MNPs) have been proposed to improve vaccination in 
developing countries and are the subject of increasing research in academia and industry 
(Figure 3.1). Microneedles are less than one millimeter long and deliver vaccines to the 
skin’s epidermis and dermis, as compared to conventional injection into deeper tissues in 
the muscle or subcutaneous space by hypodermic needle and syringe. In a MNP, an array 
of microneedles is attached to a backing such that it can be applied to the skin by hand 
like a bandage [33, 34] .  
Figure 3.1 Cumulative number of publications on microneedles and on microneedles for 
vaccination. The total number of microneedle publications was determined by searching 
the PubMed database (http://www.ncbi.nlm.nih.gov/pubmed/) on 2nd August 2015 using 
the search terms “microneedle”, “microfabricated needle”, or “nanopatch”. The subset of 
microneedle publications with focus on vaccination was determined by adding “vaccin*” 
or “immuniz*” terms to the previous search. Conference proceedings were excluded. 
*Publications from 2015 only represent those posted on PubMed by 2nd August 2015.  
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MNPs are typically designed either as solid metal, silicon or polymer 
microneedles coated with vaccine that releases the vaccine upon dissolution of the 
coating in the skin or as solid, dissolving microneedles made of water-soluble materials 
that encapsulate vaccine and releases the vaccine when the microneedles dissolve in the 
skin. While this review focuses on MNP, microneedles have also been employed for 
vaccination as solid microneedles used for skin pretreatment followed by application of a 
topical vaccine formulation for delivery through residual holes in the skin and as hollow 
microneedles for liquid vaccine formulation delivery into the skin. 
In contrast to hypodermic needles that deliver vaccine in a liquid form, MNPs 
contain the vaccine in a dried solid form which dissolves within the skin upon 
administration. Each MNP contains a single dose of the vaccine and can be easily applied 
by pressing down against the skin with the thumb or with the use of an applicator. Upon 
application of a MNP to the skin, the microneedles penetrate the skin and the patch is left 
on the skin for a few minutes to allow for dissolution to deliver the payload contained in 
it. In the case of coated MNP, the coating dissolves but not the microneedles themselves. 
In the case of dissolving MNPs, the microneedles dissolve within the skin, thus leaving 
behind only the backing and no biohazardous sharps waste.  
MNPs inherently target vaccine delivery to the skin, which is the largest 
immunological organ in the body and is densely populated by antigen-presenting cells, 
which play a crucial role in induction of immune responses. As a result, skin vaccination 
has been shown to be beneficial for many vaccines [35]. However, conventional 
intradermal injection using a hypodermic needle by the Mantoux technique can be 
difficult to perform reproducibly [36]. MNPs offer a simple and reliable way to target the 
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skin and have been studied for delivery of many vaccines [33, 34, 37, 38]. Table 3.2 
summarizes the vaccines that have been studied using microneedles; although not 
otherwise part of this review, hollow microneedles have been included in the table for 
completeness. 
Table 3.2 Vaccines studied with microneedles. 
 
    Coated 
Microneedle type 
    Dissolving 
 
       Hollow 
Adenovirus [39-42] Adenovirus [39-42] Anthrax [43-46] 
BCG [47, 48] Amyloid β peptide 
[49] 
Botulism [45, 50] 
Chikungunya virus [51] Diphtheria [52-56] Influenza [55, 57-83] 
Hepatitis B [84-87] HIV [88] Japanese encephalitis [89] 
Hepatitis C [90] Influenza [55, 57-83] Poliovirus [91] 
Herpes simplex virus [92, 
93] 
Malaria [41, 52, 94] Rabies virus [95] 
HPV [96] Measles [97] Staphylococcus aureus [43, 45] 
Influenza [55, 57-83] Poliovirus [98] Yersinia pestis [45, 99] 
Measles [100] Tetanus [52]  
Modified Vaccinia Ankara 
[39, 94] 
  
Rotavirus [101]   
Small Pox [102]   
West Nile virus [51]   
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3.3.2 Potential impact of microneedle patches for vaccination in developing 
countries 
In addition to effectively targeting the skin, MNPs offer many other advantages 
for vaccination, including addressing logistical challenges to vaccine delivery, which are 
extremely important for vaccination in developing countries. Table 3.3 summarizes the 
main advantages that MNPs offer to vaccination in developing countries. 
Table 3.3 Advantages of microneedle patches for vaccination in developing countries. 
Increased vaccine effectiveness 
Reduced need for trained healthcare providers  
Simplified supply chain 
Reduced risk of sharps 
Reduced vaccine wastage 
No need for vaccine reconstitution 
Reduced cost of vaccine/vaccination 
 
3.3.3 Increased vaccine effectiveness  
3.3.3.1 Skin vaccination enables dose sparing 
Delivering vaccines in the epidermis or dermis puts the antigen in close contact 
with the skin’s rich population of antigen-presenting cells and can result in lower doses of 
antigens being used. For example, dose-sparing using the intradermal route has been 
demonstrated in clinical studies for IPV, seasonal influenza and rabies vaccines [36, 103]. 
Since MNPs also target the skin for delivery, they could offer improved protection in 
terms of vaccine dose sparing or a wider range of immune response. In support of that 
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hypothesis, vaccination using MNPs has demonstrated dose-sparing in pre-clinical 
studies with influenza [63, 78], rotavirus [101] and herpes simplex virus [92], among 
other vaccines. 
3.3.3.2 Skin vaccination offers improved protection  
MNP vaccination has been shown to provide superior immunological responses 
by other measures as well. Vaccination at the same dose has been shown to produce 
stronger antibody and/or cellular responses when performed using MNPs compared to 
hypodermic injection [83, 104, 105], including improved immune responses in very 
young animals [104]. As a measure of protection, animals vaccinated against influenza 
using MNPs have been shown to clear virus from the lungs after challenge with live 
influenza virus better than those vaccinated intramuscularly [67, 105, 106]. Immune 
response and protection after vaccination have also been shown to last longer after MNP 
vaccination compared to intramuscular injection [107]. 
While the mechanisms responsible for the increased immunogenicity of 
vaccination using MNPs is still under study, evidence suggests that it may be due to 
vaccine delivery targeted to the unique collection of antigen-presenting cells found in the 
skin (e.g., Langerhans cells) [75, 76, 94, 108], transport of antigen and antigen-presenting 
cells from the skin to draining lymph nodes [73], adjuvanted immune response due to cell 
death caused by the trauma of microneedle insertion into skin [64, 109] , and other 
factors.   
3.3.4 Reduced need for trained healthcare providers 
The simple and minimally invasive approach of MNP delivery could allow 
administration by personnel with minimal training and also offer the possibility of self-
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administration – with or without the presence of a healthcare provider. This could enable 
vaccines that currently must be injected by trained healthcare personnel at fixed-post 
clinics to instead be administered by minimally trained personnel in house-to-house 
campaigns.  
In focus group studies of the public as well as healthcare professionals, MNPs 
were generally viewed favorably as compared to hypodermic needle injections, 
suggesting good acceptance of MNPs [110, 111]. In human studies with placebo MNPs, 
naïve subjects with no prior experience with microneedles were able to successfully 
administer MNPs when provided with only a brief set of instructions [112, 113]. MNPs 
for drug delivery have been taken home and used repeatedly by patients without 
supervision with excellent outcomes [114]. Additional analysis showed that the use of 
self-administered MNPs could improve vaccination coverage [113] and their use was 
shown to be cost effective in the majority of scenarios considered in an analysis of 
influenza vaccination in the United States [111].  
3.3.5 Simplified supply chain  
3.3.5.1 Simplified storage, distribution and disposal 
MNPs are much smaller in size than a vaccine vial and needle-syringe system, 
which could allow MNPs to be stored in a smaller volume and enable simpler storage and 
distribution [115]. For example, microneedle arrays are typically on the order of 1 cm2 in 
area and, once assembled onto a patch, could have a representative volume on the order 
of 1 cm3 [33, 37]. Although packaging, possibly in multi-dose presentations, would 
increase the product size, it is clear that MNPs have the potential to dramatically reduce 
the size of vaccines during storage, distribution and disposal.  
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3.3.5.2 Reduction or elimination of cold chain  
MNPs contain vaccines in a dried form, and suitable excipients can be used in the 
formulation to make vaccines thermostable. If sufficiently stabilized, MNP could be 
stored at ambient temperature, eliminating the cold chain completely. If only partial 
thermostability is achieved, MNPs could be refrigerated during storage at major 
distribution hubs, but then removed from the cold chain during transportation, storage at 
village clinics or mass vaccination campaigns. 
 Influenza vaccine MNPs have been studied extensively for stability at elevated 
temperatures. A recent study identified formulations stable for at least 6 months at 25 °C 
and for at least a few weeks at 40 °C [116]. Thermostability has also been studied for 
MNPs with adenovirus-based vaccines [40] and  measles vaccine, which was shown to be 
stable for at least 4 months at 25 °C and lost less than 10-fold potency after 4 months at 
40 °C [97]. 
3.3.6 Reduced risk of sharps  
MNPs contain microneedles that are a few hundred microns tall and are 
assembled on a patch backing that is applied to the skin either with thumb pressure or the 
use of a high-velocity applicator. Casual contact with a MNP is unlikely to result in 
accidental penetration of microneedles into the skin of an unintended subject, because the 
MNP needs to be placed flat against the surface of the skin and a significant force needs 
to be applied for a successful insertion [113]. MNPs could in this way reduce the risks 
associated with accidental needle stick injury to healthcare providers. 
After use, MNPs may offer additional safety advantages. Dissolving MNPs 
contain microneedles made of water-soluble, biocompatible materials that dissolve in the 
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skin after administration. Thus, they do not leave behind biohazardous sharps waste; only 
an adhesive backing that can be discarded as non-sharps waste (e.g., similar to a used 
bandage). This eliminates the risk of injury and disease transmission from used needles. 
Coated MNPs do not completely eliminate sharps waste. However, used MNPs cannot be 
reloaded with vaccine absent special coating equipment, making reuse unlikely. 
Accidental exposure to used MNPs is also expected to be safer than for hypodermic 
needles because, as mentioned above, it is difficult to get microneedles to penetrate the 
skin without an intentional, forceful application.  
3.3.7 Reduced vaccine wastage  
Each MNP contains a single dose of vaccine and is intended as a single-use 
product. In comparison to multi-dose vials, single-dose MNPs avoid the problem of 
vaccine wastage because vaccine in a multi-dose vial must be discarded before all of the 
doses are used. The single-dose format also avoids patients being turned away without 
vaccination, as sometimes occurs when an insufficient number of patients need a vaccine 
on a given day and the vaccinator does not want to open a new vial, knowing that much 
of the vaccine will be wasted [26].  
3.3.8 No need for vaccine reconstitution 
Vaccines are often lyophilized to increase vaccine stability, but this requires 
vaccine reconstitution before use. MNPs contain vaccine that is administered in a dried 
form without reconstitution that rapidly dissolves in the skin upon administration. In this 
way, MNPs can have the increased stability of a dry formulation without the time of 
clinical personnel and risk of errors associated with reconstitution.  
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3.3.9 Reduced cost of vaccine/vaccination 
3.3.9.1 Low-cost manufacturing 
In developing countries, a critical concern is the cost of vaccination. Part of that 
cost is the cost the vaccine itself. The cost-of-goods for a vaccine manufactured in a MNP 
may be similar to that of conventional vaccine vials or pre-filled syringes, depending in 
part on the type of MNP technology used. The cost of MNP manufacturing can be low in 
part because the materials are generally low-cost medical-grade polymers, metals and 
other excipients that are used in very small amounts, e.g., a representative microneedle 
array (not including the backing, adhesive and packaging) weighs less than 1 g, and the 
backing, adhesive and packaging are typically made of conventional pharmaceutical 
materials used in transdermal patches and other products.  
Manufacturing of coated MNPs typically involves a metal, polymer or silicon 
microneedle structure than can be mass-produced at low cost (e.g., < US$ 0.10), upon 
which a vaccine is coated by dipping or spraying, allowed to dry and packaged. 
Manufacturing of dissolving MNPs typically involves a polymer microneedle mold that 
can be mass produced at low cost (e.g., < US$ 0.10), onto which a vaccine is cast, 
allowed to dry and packaged. Dipping, spraying, coating and drying are all commonly 
performed in the pharmaceutical industry, which suggests that MNP manufacturing 
methods can be compatible with conventional pharmaceutical manufacturing 
environments and equipment. Much of the cost of MNP manufacturing is the need to 
perform it under aseptic conditions, which is similar to the cost structure of 
manufacturing vaccines in vials and syringes.  
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Terminal sterilization after manufacturing of microneedle patches may be 
possible, but the sterilization method will need to maintain stability of the vaccine as well 
as be compatible with the materials that microneedle patches are made of. Although 
terminal sterilization of vaccine patches has not been studied yet, electron beam and 
gamma irradiation of a microneedle patch containing a peptide therapeutic was found to 
unacceptably alter the product [117]. 
While companies have not released detailed information about their 
manufacturing methods and costs, 3M offers a solid microneedle device (sMTS) that has 
undergone FDA-approval and is available for purchase as a stand-alone device with no 
vaccine or other active. Their proprietary GMP manufacturing and aseptic coating 
technology has a capacity of up to 10,000 patches per day [118]. 
3.3.9.2 Reduced cost of vaccination 
In addition to the cost of the vaccine, the complete cost of vaccination should be 
considered, by accounting for the logistical costs of getting a vaccine delivered to a 
patient. Thus, even if the cost of a MNP vaccine is greater than a conventional one, those 
increased costs may be more than offset by reduced logistical costs, including direct costs 
of vaccine delivery and indirect costs of reduced vaccine safety, efficacy and coverage.  
As discussed throughout this section, the costs of vaccination could be reduced 
through the use of MNPs to increase vaccine effectiveness, reduce the need for trained 
healthcare providers, simplify the supply chain, reduce the risk of sharps, reduce vaccine 
wastage and eliminate the need for vaccine reconstitution. 
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3.4 Directions for future research and development 
MNPs have great potential to improve vaccination in developing countries, but more 
work needs to be done to realize this potential. Overall, translation of preclinical studies 
into clinical trials of MNP vaccination is strongly needed, as is commercial 
manufacturing that can mass produce MNPs at suitable cost. Additional considerations 
follow.  
 Increased vaccine effectiveness has been shown for a number of vaccines in animal 
models, but has not yet been established in human subjects, and the mechanisms 
associated with improved immunogenicity need further elucidation.  
  Initial studies suggest that MNPs can be reliably used by minimally trained 
personnel, including patients themselves, but more widespread assessment and 
possible improved MNP designs are needed to assure reliable vaccine delivery.  
 Reduced product size and increased vaccine thermostability are expected to 
simplify the supply chain, but the true extent of thermostability and the actual 
impact on healthcare systems have not yet been determined.  
 Reduced risk of sharps is expected, especially for dissolving MNPs. While MNPs 
reduce this risk associated with hypodermic needles, MNPs may introduce new, 
unanticipated risks that may only become apparent once they are placed in the 
hands of diverse users in diverse scenarios and cultures.  
 Reduced vaccine waste and elimination of vaccine reconstitution appear to be 
inherent capabilities of MNP vaccines, but, again, unintended consequences of 
these changes may present new challenges.  
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 The cost of MNP manufacturing remains a significant uncertainty and an 
opportunity for advances that bring down costs. Modeling can predict the possible 
cost savings associated with MNP vaccination balancing cost of goods and costs of 
vaccine delivery, but commercial and clinical implementation will be needed to 
determine the true cost, which will vary based on vaccine and use scenario. 
Identification of terminal sterilization methods that avoid the need for costly 
aseptic manufacturing could significantly reduce the costs of MNP products.  
 
 
3.5 Conclusions 
Many lives could be saved by improved vaccination in developing countries. MNPs 
offer advantages that could improve vaccination through increased vaccine effectiveness, 
reduced need for trained healthcare providers, simplified supply chain, reduced risk of 
sharps, reduced vaccine wastage, no need for vaccine reconstitution and reduced cost of 
vaccine/vaccination. With continued development, especially translation into clinical 
trials and advanced manufacturing, MNPs have great potential to address the limitations 
of current vaccination methods and thereby improve vaccination in developing countries.  
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CHAPTER 4 
RABIES VACCINATION IN DOGS USING A DISSOLVING 
MICRONEEDLE PATCH 
 
4.1 Abstract 
Because humans get rabies primarily through dog bites, mass vaccination of 
domestic dogs and other animals has virtually eliminated human rabies in industrialized 
countries. However, thousands of people in developing countries die of rabies each year 
due to lack of mass vaccination because of financial, logistical and other challenges. 
Here, we propose the use of dissolving microneedle patches for simple, cost-effective 
rabies vaccination and assess the safety and immunogenicity of microneedle patch 
vaccination using a rabies DNA vaccine in dogs.  The vaccine was stable upon 
formulation and storage for at least 3 weeks at 4 °C in a microneedle patch. For 
vaccination, the patches were applied to the inner ear by hand without an applicator, 
Microneedle patches were well tolerated in the skin, with mild erythema, minimal wheal 
formation and complete resolution of skin reactions within 7 days, and generated no 
systemic adverse events. Microneedle patches were at least as immunogenic as 
intramuscular injection at the same dose, as demonstrated by similar serum neutralizing 
antibody titers. A ten-fold lower vaccine dose administered by microneedle patch 
generated a weaker immune response compared to full-dose intramuscular vaccination. 
We conclude that dissolving microneedle patches may serve as an innovative approach to 
mass vaccination of dogs.  
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4.2 Introduction 
Rabies is an acute, often fatal encephalitis caused by viruses in the Rhabdoviridae 
family [1]. The disease is zoonotic and human infection usually results from a bite or 
scratch from an infected animal or direct contact of skin wounds with virus containing 
saliva. Although all warm-blooded animals can be reservoirs of rabies, dogs account for 
99% of human deaths due to rabies and pose a potential threat to more than 3.3 billion 
people [2]. 
Human rabies has been almost eliminated in industrialized countries by 
widespread and often mandatory vaccination of dogs and other animals, as well as the 
availability of vaccines for humans [3]. Humans are not typically vaccinated against 
rabies for prevention, but post-exposure prophylactic vaccines and immunoglobulins are 
available to people who become exposed to the virus [4]. These measures have caused 
the number of deaths due to rabies in the United States to drop to just one to two per year 
[5]. However, globally, an estimated 26,000 to 61,000 deaths are caused by rabies each 
year, more than 95% of which occur in Africa and Asia due to dog bites [3]. Rabies 
occurs mainly in remote rural communities where children between the age of 5–14 years 
are the most frequent victims [6], and limited access to healthcare facilities with the high 
cost and complex schedule of post-exposure vaccines for humans often makes it difficult 
to provide medical care to people that become exposed to the virus [7].  
In developing countries, more extensive vaccination of dogs and humans is often 
limited by the high cost of vaccination and a lack of trained personnel to administer the 
vaccines. Intradermal vaccination using one-fifth to one-tenth the dose of rabies vaccine 
has been shown to be effective in humans, thereby enabling significant cost savings [2, 8-
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10]. This dose sparing is believed to be due to targeting of the vaccine to resident 
dendritic cells in the skin, such as Langerhans and dermal dendritic cells, which are able 
to mount a more robust immune response [11-13]. However, intradermal injection 
requires specifically trained healthcare personnel and successful injection into the skin is 
unreliable [14, 15]. Thus, low-cost intradermal post-exposure prophylaxis of humans is 
sometimes available, but intradermal pre-exposure vaccination in dogs is generally not. A 
simple and reliable method of intradermal rabies vaccination could therefore enable more 
widespread vaccination at lower cost.  
Another method of cost savings is through DNA vaccination. Human DNA 
vaccines could be much less costly to manufacture compared to inactivated virus 
vaccines. This is because human DNA vaccines can be produced in large quantities by 
bacterial fermentation processes and may not require expensive facilities with high 
biosafety levels for production [16]. 
In this study, we propose that delivery of a rabies DNA vaccine using a 
microneedle patch could enable more widespread rabies vaccination of dogs and humans 
by enabling minimally trained personnel to carry out vaccination.  Microneedles are less 
than one millimeter long and deliver vaccines to the skin’s epidermis and dermis using a 
patch that is simply and painlessly applied to the skin by personnel with minimal training 
[17-22]. In a dissolving microneedle patch, an array of microneedles is attached to a 
backing such that it can be applied to the skin by hand like a bandage. After insertion into 
the skin, the microneedles dissolve in the skin within minutes, thereby delivering the 
vaccine contained in them and not generating sharps waste [23-33].  
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Vaccination using a microneedle patch could simplify rabies vaccination of dogs, 
especially stray dogs in developing countries, since the microneedle patches could be 
easily applied by hand on a dog’s ears by personnel with minimal training. While oral 
rabies vaccine exist, it has limited use when vaccinating dogs because the bait in which 
the vaccine is contained does not always lead to complete delivery of vaccine and the use 
of oral vaccines is usually limited to areas with minimal human activity so as to ensure 
safe distribution [3]. Post-exposure rabies prophylaxis could also reach more patients by 
enabling vaccination by minimally trained personnel without the need to go to qualified 
healthcare facilities. Microneedle patch vaccination could also be attractive in 
industrialized countries, where dogs and their owners may prefer a painless, less-invasive 
method of vaccination. 
Microneedle patches have previously been studied for delivery of a number of 
vaccines for eventual human applications [34-41], but have not previously been studied 
for rabies vaccination or for veterinary vaccination applications. The goal of this project 
is to develop an easy-to-administer rabies vaccine suitable for use in dogs that enables 
cost savings, is safe and is at least as immunogenic as conventional intramuscular 
vaccination. We therefore developed and characterized dissolving microneedle patches 
for rabies vaccination and then assessed safety and immunogenicity in a small clinical 
study in beagle dogs. 
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4.3 Materials and methods 
4.3.1 Fabrication of microneedle patch 
Polydimethylsiloxane (PDMS) molds containing a 10 x 10 array of conical 
microneedles (base diameter 300 µm and height 650 µm) were used for microneedle 
patch fabrication by a two-step micromolding process. (i) Vaccine fill: The vaccine (i.e., 
proprietary DNA plasmid provided by Merial Inc. isolated from E. coli culture using the 
EndoFree Plasmid Giga Kit (Qiagen, Germantown, ND)) was mixed 1:1 with 15% w/v 
sucrose (Sigma-Aldrich, St. Louis, MO) and applied to the microneedle mold. Vacuum 
was then applied for 45 min. Excess vaccine was removed and the mold was allowed to 
dry for 90 min. (ii) Polymer matrix fill: The polymer matrix solution was composed of 
polyvinyl alcohol (EMD Millipore, Billerica, MA) and sucrose (Sigma-Aldrich) in sterile 
water. The solution was heated to 80 °C for 6 h before use to facilitate dissolution of the 
polyvinyl alcohol. The matrix solution was applied onto the mold and exposed to vacuum 
for 4 h. The mold was left in a chemical hood overnight to dry.  
To remove the dried microneedle patches, a 2.3 cm-diameter disc of 
polymethylmethacrylate (McMaster-Carr, Atlanta, GA) was covered on one side with 
double-sided tape (MacTac, Stow, OH) and applied to the back of the mold. The resulting 
patch was gently peeled away from the mold and stored in a dark, sealed pouch with 
desiccant at 4 °C until use.  
As a quality control measure, a representative sample of patches from each batch 
was tested for DNA loading, supercoiling and sterility, as described below. Microneedle 
patches were imaged by brightfield microscopy (SZX12, Olympus, Center Valley, 
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Pennsylvania). Microneedle patches were applied to the animals for vaccination three 
weeks after fabrication, as described below, after all testing had been completed. 
4.3.2 Quantification of DNA loaded into microneedle patch 
DNA concentrations were measured using the nucleic acid setting on Nanodrop 
2000 (Thermo Fisher, Waltham, MA). The patch was dissolved in deionized autoclaved 
water to determine the dose contained in the patch. A placebo patch containing no 
vaccine was used as a negative control to subtract any interference from the microneedle 
matrix materials. 
4.3.3 Quantification of DNA supercoiling 
DNA supercoiling was measured using agarose gel electrophoresis. A 0.8% 
agarose gel was run with Tris-acetate buffer and the gel was stained with ethidium 
bromide. The gel was imaged using a Kodak 200 gel logic camera system (Kodak, 
Rochester, NY) and the relative intensities of the bands were used to calculate the 
percentage of supercoiled DNA. 
4.3.4 In-vitro expression assay for DNA stability 
An in-vitro expression assay was used to confirm the ability of the vaccine to 
express the rabies G protein in-vitro (i.e., the vaccine antigen). CHO-K1 cells (ATCC 
CCL-61, American Type Culture Collection, Manassas, VA) were transfected with rabies 
DNA obtained from reconstituted patches using Lipofectamine (Life Technologies, 
Carlsbad, CA) and stained with mouse anti-rabies glycoprotein monoclonal antibody 
clone 24-3F-10 (EMD Millipore, Billerica, MA) and FITC-conjugated rabbit anti-mouse 
IgG (Sigma, St. Louis, MO). For a sample to be declared satisfactory, cells needed to 
show easily visible and similar level of green fluorescence as compared to the control.  
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4.3.5 Insertion of microneedle patches into dog ears ex-vivo 
Excised dog ears were obtained from animals euthanized as part of a separate 
study and the skin was carefully shaved with a razor to remove fur. Microneedle patches 
containing sulforhodamine dye (to simulate vaccine) were applied to the skin on the inner 
ear pinna by pressing down with the thumb, left on the skin for 15 min and then removed. 
The skin site and microneedle patches were imaged before and after insertion.  
4.3.6 Safety and immunization study 
The study was approved by the Institutional Animal Care and Use Committees 
(IACUC) at Merial and Georgia Tech. Male and female beagle dogs aged 5 to 11 months 
were used in the clinical study. The dogs were seronegative for rabies and were excluded 
from the study if they had eczema or inflammation at the injection sites at the time of the 
study. The dogs were vaccinated by intramuscular (IM) injection (50 µg DNA), 
microneedle patch (50 µg DNA) and microneedle patch (5 µg DNA) (n=5 per group). A 
placebo (i.e., no vaccine) microneedle patch group was also included in the study (n=2). 
Four weeks after the first dose, all dogs were given a booster using the same route and 
dose as the initial vaccination (Figure 4.1).  
 
Figure 4.1. Outline of vaccination timeline. After a 7 day acclimation period, prime 
vaccination was carried out, followed by a boost vaccination 28 days later. The skin was 
shaved three days prior to each vaccination. Blood was collected 14, 25, 42 and 56 days 
after the prime vaccination.  
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Microneedle patches were applied on the inner ear pinna. Fur was removed from 
the inner ear surface by shaving with a disposable razor and shaving cream three days 
prior to each vaccination. During vaccination, the ear was gently held on top of one hand 
and the patch was applied using the other hand by pressing down on the backing with the 
thumb for 1 min. The patches were secured onto the ear with 3M™ VetRap™ Bandaging 
Tape and left on the skin for up to15 min. The patches were then removed from the skin 
and stored for imaging. Intramuscular injections were administered to the rear leg in the 
caudal thigh muscle using a conventional 22 gauge needle and syringe. All dogs were 
awake during the vaccinations without sedation or pain relieving drugs.  
Tolerance to injection was noted during each vaccination. Dogs were considered 
intolerant of injection if they vocalized, withdrew or tried to bite upon injection. Dogs 
were observed for local injection site reactions on the day of the vaccination, daily for the 
first three days following vaccination and intermittently for any dogs with reactions 
persisting for more than 3 days. Local injection sites were assessed by blinded personnel 
for erythema, wheal formation, swelling, pain upon palpation and ulceration.  Rectal 
temperatures were recorded in conjunction with injection site observations. Blood was 
collected prior to beginning the study and every two weeks until the end of the study at 
eight weeks. 
4.3.7 Measurement of neutralizing antibodies 
Serum was separated from blood and stored at -20 °C. Serum samples were 
submitted to Atlanta Health Associates (Cumming, GA) for analysis of anti-rabies 
neutralizing antibody titers using the rapid fluorescent focus inhibition test (RFFIT). 
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Results were expressed in international units per milliliter of serum (IU/ml) and titers 
greater than 0.2 IU/ml were considered seropositive. 
4.3.8 Statistics 
 Statistical analysis was carried out using Prism software version 5 (Graphpad, La 
Jolla, CA). P values < 0.05 were considered significant. Average values of degree of 
supercoiling were analyzed using one-way ANOVA with Dunnett’s multiple comparison 
post-test.  
 
4.4 Results 
4.4.1 Vaccine stabilization in microneedle patches  
Microneedle patches were formulated with biocompatible, water-soluble 
excipients so that microneedles could dissolve in the skin, thereby releasing encapsulated 
vaccine. These dissolving microneedle patches were fabricated as a 10 x 10 microneedle 
array in a ~1 cm2 area affixed to a clear plastic backing (Figure 4.2A). Compared to 
conventional needle-and-syringe vaccination, the microneedle patches were designed to 
be small (Figure 4.2A, B), generate no sharps waste and be simple to apply by minimally 
trained personnel.  
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Figure 4.2 (A) Picture of a 10-dose vaccine vial, 10 conventional needles and syringes 
and a sharps waste container next to 10 microneedle patches. Inset: A 100-microneedle 
array made of water-soluble polymers and sugars containing sulforhodamine dye. (B) 
Magnified image of a microneedle patch containing sulforhodamine dye placed adjacent 
to a 22-gauge needle for scale.  
 
Because vaccine is dried during fabrication of microneedle patches, a suitable 
formulation was developed to maintain vaccine activity during the fabrication process. 
Sucrose has previously been used in formulations to stabilize various vaccines during 
drying [42, 43]. Microneedle patches were therefore fabricated with sucrose as the 
stabilizing excipient during the vaccine fill step and stored in a sealed foil pouch with 
desiccant. Before use in the clinical study, the patches had to be stored for three weeks to 
allow sufficient time to complete sterility testing, during which time the vaccine in the 
patch needed to remain stable. We therefore stored the microneedle patches for three 
weeks at 4 °C and assessed DNA vaccine stability by two methods: maintenance of DNA 
supercoiling and in-vitro transfection of cells. The patches containing 50 µg DNA 
vaccine were able to meet the stability requirements for the study as seen by no 
significant loss in supercoiling (Figure 4.3B) as compared to the liquid control and 
successful in-vitro transfection of cells demonstrated by expression of rabies G protein (p 
> 0.05, Figure 4.3A). Microneedle patches containing the 5 µg DNA vaccine dose 
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showed some loss in supercoiling (p < 0.05, Figure 4.3B), but exhibited successful in-
vitro transfection (Figure 4.3A). Both microneedle patch groups also passed the sterility 
test (data not shown) and were therefore considered suitable for clinical testing. 
 
 
Figure 4.3 Effect of microneedle fabrication and storage on DNA vaccine stability. 
Microneedle patches were packaged in a foil pouch with desiccant and stored in a 
stability chamber at 4 °C for three weeks. (A) Representative images from in-vitro 
expression assay (green-stained cells indicate expression of rabies G protein encoded in 
the DNA vaccine). (B) Degree of supercoiling of DNA. Data points represent the average 
± standard deviation (SD) from n=3 independently tested samples.  Asterisk (*) indicates 
a significant difference (p <0.05) from liquid control.  
 
4.4.2 Microneedle patch insertion into skin 
In addition to vaccine stability, microneedle patches also needed to be mechanically 
strong in order to pierce the stratum corneum and insert into the skin. Microneedle 
patches containing a pink dye (i.e., sulforhodamine, to simulate vaccine) were applied to 
the skin of dog ears ex-vivo by pressing on the patch backing with the thumb (i.e., no 
applicator was used). We wanted to avoid the use of an applicator device because it adds 
 64 
bulk and cost to the microneedle patch, and the goal was to design a device that is small 
and easy to administer. The microneedles dissolved in the skin within 15 min of 
application, as seen by the 10 x 10 grid of pink dye deposited in the skin (Figure 4.4A, 
B), as well as the disappearance of microneedle tips containing the dye shown by 
microscopy (Figure 4.4C, D). It is important to note that most of the dye (or vaccine) is 
concentrated in the tips of the microneedles, such that complete insertion and dissolution 
of the microneedle is not needed to deliver the dye/vaccine into the skin.  
 
Figure 4.4 Representative images of insertion and dissolution of microneedles after patch 
application to dog ears ex vivo. Microneedle patches were applied to shaved skin by 
pressing down with the thumb, left on the skin for 15 min and then removed. (A) 
Microneedle patch containing sulforhodamine dye applied to skin. (B) Same section of 
skin imaged after microneedle patch application and removal, which shows a grid where 
microneedles punctured the skin and delivered the dye. Microneedle patches (C) before 
and (D) after insertion into skin. The dye was concentrated in the tip of the microneedles 
whereas the base of the microneedles contained very little dye.  
 
4.4.3 Safety of rabies vaccination of dogs using a microneedle patch 
Beagle dogs were vaccinated with a prime dose and a booster dose 28 days later using 
microneedle patches at a 50 µg or 5 µg dose, IM injection at a 50 µg dose, and a placebo 
microneedle patch containing no vaccine. During vaccination, the dogs were noted for 
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intolerance to vaccine administration as indicated by vocalization, withdrawal or 
attempted biting. During prime vaccination, 60% of the dogs in the IM injection group 
were intolerant of injection, whereas none of the dogs in any of the microneedle patch 
groups showed signs of intolerance. During boost vaccination none of the dogs in the IM 
injection group, the 50 µg patch group or the placebo patch groups showed signs of 
intolerance, whereas one dog (20%) in the 5 µg microneedle patch group showed signs of 
intolerance (Table 4.1).  
Table 4.1 Tolerance of dogs to vaccination by IM injection and microneedle patch. 
 
 Prime 
(Day 0) 
Boost 
(Day 28) 
Intramuscular injection 50 µg   
Microneedle patch 50 µg   
Microneedle patch 5 µg   
Placebo microneedle patch   
 
1Dogs were considered intolerant of injection if they vocalized, withdrew or tried to bite 
upon injection. 
 
The vaccination sites were monitored for local skin reactions. After removal of 
microneedle patch from the skin, a faint grid of the needles puncturing the skin was 
visible with slight erythema as well as minor redness along the edges of the patch. A 
small drop of blood (< 1 µL) was also visible in most insertions (Figure 4.5).  
Dogs were 
tolerant 
Dogs were 
intolerant 
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Figure 4.5 Dog ear during and after microneedle patch vaccination in vivo. Microneedle 
patches were applied onto dog ears with hair removed, left on the skin for 15 min and 
then removed.  (A) Microneedle patch applied to skin. (B) Same section of skin 
immediately imaged after microneedle patch application and removal showing a faint 
grid where microneedles inserted and slight skin erythema. 
 
All (100%) of the dogs in the microneedle vaccination groups showed mild 
transient erythema at the vaccination site, whereas only 50% of the dogs in the 
microneedle placebo group showed erythema. None of the dogs in the IM injection group 
showed erythema at the injection site (Table 4.2). Most skin erythema resolved within 4 
days and all erythema resolved within 7 days (Table 4.3 and 4.4).  
Table 4.2 Number and type of local injection site reactions.  
 
Erythema 
Wheal 
Formation 
Swelling 
Pain 
upon 
palpation 
Ulceration 
IM 50 µg      
MN 50 µg      
MN 5 µg      
MN Placebo      
 
1The dogs were observed for local injection site reactions on the day of the vaccination, 
daily for the first three days following each vaccination and intermittently for any dogs 
with reactions persisting for more than three days. This table reports the cumulative 
percentage of dogs with injection site reactions after both vaccinations.  
 
 
Skin 
reactions 
absent 
Skin 
reactions 
present 
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Table 4.3 Duration of erythema after prime vaccination. 
 
 % Of 
dogs with 
Erythema 
% Resolving in 
3 Days 4 Days 7 Days 
IM 50 µg     
MN 50 µg     
MN 5 µg     
MN Placebo     
 
 
 
 
Table 4.4 Duration of erythema after boost vaccination. 
 
 % Of 
dogs with 
Erythema 
% Resolving in 
2 Days 3 Days 4 Days 7 Days 
IM 50 µg      
MN 50 µg      
MN 5 µg      
MN Placebo      
 
 
Vaccination sites were also monitored for wheal formation: 20% of dogs in the 50 
µg microneedle group, 40% of dogs in the 5 µg microneedle group and 50% of dogs in 
the placebo microneedle group showed wheal formation (Table 4.2). None of the dogs in 
the IM injection group showed wheal formation. All wheal formation resolved within 2 
days (Table 4.5 and 4.6). There was no swelling, pain upon palpation, ulceration or any 
other abnormality noted at the vaccination site. The veterinary staff noted no other study 
related health problems in the dogs, and there were no systemic adverse events reported.  
 
Skin 
reactions 
absent 
 
Skin 
reactions 
present 
 
 
Skin 
reactions 
absent 
 
Skin 
reactions 
present 
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Table 4.5 Duration of wheal formation reaction after prime vaccination.  
 
 % Of dogs 
with 
Wheal 
% Resolving 
 in 2 Days 
IM 50 µg   
MN 50 µg   
MN 5 µg   
MN Placebo   
 
 
 
 
 
 
Table 4.6 Duration of wheal formation reaction after boost vaccination 
 % Of dogs 
with 
Wheal 
% Resolving 
 in 2 Days 
IM 50 µg   
MN 50 µg   
MN 5 µg   
MN Placebo   
 
 
4.4.4 Immunogenicity of rabies vaccination of dogs using a microneedle patch 
Immune response following rabies vaccination was also evaluated. Beagle dogs were 
selected as the study subjects because they are representative of a major population that 
receives rabies vaccination (i.e., dogs) and can serve as a model for humans and other 
animals. Fourteen days after prime vaccination, none of the groups showed meaningful 
increases in rabies-specific, neutralizing antibody titers (Figure 4.6). On day 25, 60% of 
dogs in the IM vaccination group, 40% of dogs in the 50 µg microneedle patch group and 
Skin 
reactions 
absent 
Skin 
reactions 
present 
 
Skin 
reactions 
absent 
Skin 
reactions 
present 
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20% of dogs in the 5 µg microneedle patch group were seropositive (Figure 4.7), but 
most had very low antibody titers. On day 42, fourteen days after the boost vaccination, 
antibody responses were much higher, with mean titers similar between the 50 µg 
microneedle group and the IM vaccination group at the same dose, whereas on day 56 the 
mean titer in the 50 µg microneedle group was higher than after IM vaccination at the 
same dose. However, due to the small number of animals per group and the variability in 
titers within each group, statistically significant differences were not seen. Overall, 100% 
of animals were seropositive in both the 50 µg microneedle and IM vaccination groups 
on day 42 and 56 with antibody titers well above threshold, which indicates that 
microneedle patch vaccination produced an equivalent immune response to conventional 
IM vaccination.   
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Figure 4.6 Neutralizing antibody titers after vaccination using microneedle patch as 
compared to conventional intramuscular injection. Dogs were vaccinated with either a 
microneedle patch (MN) containing no vaccine (placebo), a microneedle patch containing 
5 µg or 50 µg vaccine or a conventional intramuscular injection (IM) containing 50 µg 
vaccine. Blood was collected from the dogs at each of the given time points and tested 
independently. Neutralizing antibodies were measured using the RFFIT assay and 
expressed in International Units per milliliter (IU/ml). Data points show the individual 
antibody titers and column bars represent the geometric mean titer. 
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Figure 4.7 Percentage of dogs seropositive within the different microneedle (MN) and 
intramuscular (IM) groups before and after the boost. Pre-boost data are shown for day 
25. Post-boost seropositivity remained the same at day 42 and 56. Seropositivity was 
defined as a titer > 0.2 IU/ml.   
 
While the 5 µg microneedle patch group exhibited an increased immune response, 
there was no evidence of dose sparing, since the 5 µg microneedle patch group had lower 
mean titers and seropositivity rates compared to the IM vaccination group. The placebo 
microneedle group had no rabies-specific neutralizing antibodies, and none of the animals 
were seropositive, as expected.  
 
4.5 Discussion 
The goal of this study was to develop a small, sharps-free and easy-to-administer device 
for rabies vaccination of dogs such that it contains the required dose of the vaccine, is 
safe, is at least as immunogenic as conventional IM vaccination and enables cost savings.  
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Dissolving microneedle patches could enable simpler administration of vaccines. 
In this study, microneedle patches were applied to dog ears with gentle manual force (i.e., 
without the need for an applicator device) and left in place for a few minutes. The 
microneedles dissolved in the skin and did not leave behind sharps waste. The dogs 
tolerated the microneedle patch very well, and better than the first intramuscular 
injection. Future work will address reducing the time of patch application to as little as a 
few seconds and elimination of the need to shave the skin. Altogether, microneedle patch 
vaccination could enable simpler administration of rabies vaccine to dogs, including stray 
dogs in developing countries, and could be applied by minimally trained workers, which 
would reduce the need for personnel trained to give hypodermic injections. In 
industrialized countries, microneedle patches could be an attractive sharps-free 
alternative to intramuscular injection in the veterinary setting. 
Rabies vaccination using microneedle patches was well-tolerated in the skin, and 
there were no systemic adverse events reported. Only mild, transient erythema was 
observed, which resolved within a few days, was not sensitive to touch and did not result 
in other sequelae.  
Prior studies have shown excellent thermostability of vaccines in microneedle 
patches [27, 44, 45]  and DNA has been shown to be stable during storage in a dried state 
[34, 46-49].  While this study only assessed stability for three weeks at 4 °C, future 
studies should evaluate stability at higher temperatures for extended periods to determine 
if microneedle patches can avoid the need for storage and transportation in the cold chain, 
which would be of significant value in developing countries that often lack access to 
reliable refrigeration [50, 51].  
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Microneedle patch vaccination produced a strong rabies-specific immune 
response. Antibody titers after vaccination by microneedle patch were similar to 
intramuscular vaccination at the same dose in this study and were similar to responses to 
intramuscular vaccination in previous studies using rabies DNA vaccine [52]. The 
neutralizing antibody titers were well above 0.5 IU/ml, which is considered protective in 
humans [53]. However, the dogs were not challenged with rabies virus to evaluate 
survival in this study. 
Intradermal delivery has been shown to enable dose sparing for a number of 
vaccines, including rabies [11, 32, 54, 55]. However, we did not see evidence for ten-fold 
dose sparing in this study. It is possible that the vaccine patch developed in this study 
could enable dose sparing at reductions less than ten-fold.  
One of the goals of this study was to assess possible cost savings due to rabies 
vaccination using a microneedle patch. Cost savings relative to conventional 
intramuscular vaccination could result from the use of minimally trained (i.e., lower cost) 
personnel to perform vaccination and the use of a DNA vaccine, which is expected to be 
relatively inexpensive to manufacture compared to the cost of traditional human vaccines 
[56].  Further cost savings could result from  possible thermostability, which has been 
demonstrated for other microneedle patch vaccines and DNA vaccines [44, 45, 57, 58], 
and the possibility of dose sparing, which was not seen in this study at the doses used but 
has been demonstrated for microneedle patch vaccines and, more specifically, 
intradermal delivery of rabies vaccines [8-10, 59]. Also, manufacturing of microneedle 
patches is expected to be inexpensive, i.e., less than the cost of a needle, syringe and 
vaccine-filled vial [19].  
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This study used beagle dogs, which are commonly used in veterinary research as a 
model dog breed [60]. This study therefore serves as a first-in-dogs clinical trial for 
veterinary vaccine applications. Dogs have been used before as an animal model for 
insulin delivery using microneedles [61].  
 
 
4.6 Conclusions 
This study has shown for the first time that dissolving microneedle patches can 
safely and effectively administer rabies DNA vaccine to dogs using a delivery technology 
that is easy to administer and may enable cost savings. The vaccine was stable upon 
formulation and storage for at least 3 weeks at 4 °C in a microneedle patch. The patches 
were administered manually to dog ears by pressing with the thumb, without the need of 
an applicator, and the microneedles dissolved in the skin within 15 min, thereby leaving 
no sharps waste.  
Microneedle patches were well tolerated in the skin with mild erythema, minimal 
wheal formation and complete resolution of skin reactions within 7 days, and generated 
no systemic adverse events. Microneedle patches were at least as immunogenic as 
intramuscular injection at the same dose, as demonstrated by similar serum neutralizing 
antibody titers. A ten-fold lower vaccine dose administered by microneedle patch 
generated a weaker immune response compared to full-dose intramuscular vaccination.  
In contrast to traditional needle-and-syringe vaccination, these microneedle 
patches were designed to enable administration by minimally trained personnel, increase 
safety by generating no sharps waste and utilize a DNA vaccine that is relatively 
inexpensive to manufacture compared to traditional human vaccines, all of which are 
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expected to enable increased vaccination coverage at reduced cost. For these reasons, 
dissolving microneedle patches may serve as an innovative and effective approach to 
mass vaccinate dogs and humans. 
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CHAPTER 5 
TOLERABILITY, USABILITY AND ACCEPTABILITY OF 
DISSOLVING MICRONEEDLE PATCH ADMINISTRATION IN 
HUMAN SUBJECTS WITHOUT AN APPLICATOR 
 
5.1 Abstract 
To support translation of microneedle patches from pre-clinical development into 
clinical trials, this study examined the effect of microneedle patch application to local 
skin reactions, reliability of use and acceptability to patients. Placebo patches containing 
dissolving microneedles were administered to fifteen human participants. Microneedle 
patches were very well tolerated in the skin with no pain or swelling and only minimal 
erythema localized to the site of patch administration that resolved fully within seven 
days. Microneedle patches could be administered reliably by hand without the need of an 
applicator and delivery efficiencies were similar for investigator-administration and self-
administration. Microneedle patch administration was not considered painful and the 
large majority of subjects were at least somewhat confident that they self-administered 
patches correctly. Microneedle patches were overwhelmingly preferred over conventional 
needle and syringe injection. Altogether, these results demonstrate that dissolving 
microneedle patches were well tolerated, easily usable and strongly accepted by human 
subjects, which will facilitate further clinical translation of this technology. 
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5.2 Introduction 
Microneedle patches contain hundreds of microneedles less than one millimeter 
long to deliver drugs and vaccines into the skin. In a dissolving microneedle patch, an 
array of microneedles is attached to a backing such that it can be applied to the skin. The 
microneedles dissolve in the skin within minutes, thereby delivering the vaccine 
contained in them and not generating sharps waste. Microneedle patches offer advantages 
over conventional drug delivery by needle and syringe.  
Microneedle patches have previously been studied for delivery of a number of 
drugs and vaccines in pre-clinical studies [1-9] but limited information is available about 
the use of dissolving microneedle patches in human subjects. Microneedle patches are 
typically designed either as coated microneedle patches made of solid metal, silicon or 
polymer microneedles coated with vaccine that releases the vaccine upon dissolution of 
the coating in the skin or as dissolving microneedle patches containing solid, dissolving 
microneedles made of water-soluble materials that encapsulate vaccine and release the 
vaccine when the microneedles dissolve in the skin [9, 10].  
Coated microneedle patches are being evaluated in clinical trials for delivery of 
parathyroid hormone to treat osteoporosis [11], glucagon to treat hypoglycemia [12] and 
zolmitriptan to treat migraine [13]. However, given the difference in delivery 
mechanisms of coated and dissolving microneedles, all the results from coated 
microneedle patches cannot be directly applied towards studying dissolving microneedle 
patches. Dissolving microneedle patches are being evaluated in clinical trials for delivery 
of parathyroid hormone [14] as well as influenza vaccination [15, 16].  
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Both of these microneedle patch types have been studied using a high velocity 
insertion device, which while effective in delivery of microneedle patches, adds 
additional bulk and cost to the microneedle device. In this study, we are examining the 
usability of dissolving microneedle patches without the use of an applicator for the first 
time in human subjects. To our knowledge, no other study has evaluated the puncture and 
delivery efficiencies of dissolving microneedle patches in humans or the acceptability 
preferences regarding vaccination using dissolving microneedle patches. As dissolving 
microneedle patches continue being developed for clinical translation in the next few 
years, it is important to fully characterize the insertion and dissolution of microneedles in 
humans. Reliably administering the microneedle patches in a way that ensures complete 
insertion and delivery of the vaccine into the skin will be key factors to enable clinical 
use, including the possible use of microneedle patches applied by hand without the use of 
an applicator. 
The goal of this study is to evaluate skin tolerability, usability and acceptability of 
dissolving microneedle patches to further clinical translation of microneedle patches for 
delivery of drugs and vaccines. In order to prepare for a phase 1 clinical trial of influenza 
vaccination using microneedle patches of a similar design [17], we conducted a human 
study with placebo microneedle patches to study these parameters in greater detail. We 
therefore developed placebo dissolving microneedle patches and conducted a human 
study assessing reactions in the reactions in the skin after microneedle patch application, 
microneedle patch delivery efficiency in investigator-administration and self-
administration and conducted a survey about participant’s preferences about microneedle 
patch administration. 
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5.3 Materials and methods 
5.3.1 Fabrication of dissolving microneedle patch 
Microneedle arrays were fabricated using a micromolding process similar to that 
described before [1] to produce microneedle patches containing 100 microneedles in a ~1 
cm2 area  that were adhered to a flexible paper backing that incorporated a force-feedback 
indicator that made a clicking sound when a force greater than 13 lbf is applied. 
Microneedle patches were stored in a sealed foil pouch with silica gel desiccant until used 
at the time of study.  
5.3.2 Study approval and study subjects 
This study was approved by the Georgia Institute of Technology Institutional 
Review Board and informed consent was obtained from all participants. To be eligible, 
participants had to be healthy non-pregnant adults with normal skin, no known problems 
with pain perception and no known allergies to the materials used in the study. 
Participants could not have previously seen or worked with microneedle patches to be 
eligible for the study. Fifteen subjects (seven females and eight males), ages 18 - 57 were 
recruited from the Georgia Institute of Technology and other sites in Atlanta, GA. 
5.3.3 Experimental design 
Participants received three microneedle patches – one self-administered and two 
investigator-administered. Participants were provided a brief overview of the study and 
watched a short presentation on self-administration of microneedle patches. An outline of 
microneedle patch administration process is outlined in Figure 5.1.  
Participants first self-administered a microneedle patch to their forearm without 
assistance from the investigator. The investigator stained this skin site (see below). The 
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investigator then applied two microneedle patches to the participant, one on each 
forearm. Only one of these skin sites was stained by the investigator. The site not stained 
was used to make measurements of skin tolerability (see below). The investigator-
administration stained site and the self-administration stained site were used for usability 
measurements (see below).  
Participants then answered a questionnaire about microneedle patch 
administration for acceptability measurements. Participants returned to the study site on 
days 1, 2, 3, 4 and 7 after microneedle patch administration for skin tolerability 
measurements. 
 
Figure 5.1 Procedure to apply a microneedle patch to the skin. (A) Subject or 
investigator picks up the patch with the dominant hand and removes the protective cap. 
(B) Subject forms a fist in the non-dominant hand and then subject or investigator places 
the patch on the forearm. Subject or investigator pushes on the patch with the thumb and 
continues to apply force until hearing a ‘click’ sound, indicating that enough force has 
been applied. (C) Subject leaves the patch on the skin for 20 minutes after which patch 
application is complete. Subject or investigator peels away the patch from the skin and 
the investigator saves the patch for additional analysis. 
5.3.4 Skin tolerability measurements 
Skin tolerability was measured using the skin scoring scale listed in the appendix 
table A.1. The scale was created for microneedle patches using guidelines available for 
vaccine clinical trials and clinical testing of transdermal patches [18, 19]. The skin site 
was scored for pain, tenderness, erythema (size and intensity) and induration or swelling 
A 
 
B 
 
C 
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on a grading scale of 0 to 4. Pain and tenderness were scored based on the participant’s 
response whereas erythema and swelling were measured by the investigator.  
Participants were asked if they felt any pain at the skin site after microneedle patch 
administration was complete. This pain is separate from the pain during microneedle 
patch application, which is noted in usability measurements. Tenderness was defined as 
any pain felt at the skin site when the investigator gently touched the skin site. Erythema 
size was measured using a ruler scale and intensity by visual observation of the skin site. 
Since there were no erythema scale for microneedle patches already in place, the 
investigator was trained on erythema measurements using guidelines and training 
available for Psoriasis Area Severity Index (PASI) scores [20]. Swelling was measured 
by the investigator by gently moving the thumb over the skin site to notice any raised 
surfaces in the skin. Investigator noted a score for all of the criteria and photographically 
imaged the skin at each time point.  
5.3.5 Skin staining and microscopy to measure usability  
Usability was measured in terms of microneedle puncture efficiency by skin 
staining (percentage of microneedles that penetrated the skin surface) and delivery 
efficiency by microscopy (percentage volume of microneedles that dissolved after 
administration). Skin was stained using gentian violet 1% solution (Humco, Texarkana, 
TX). Immediately after microneedle patch administration, gentian violet was pooled on 
the skin site for 1 min, dabbed with gauze and cleaned with alcohol after 10 min. The 
stained skin site was imaged and microneedle puncture efficiency was measured by 
counting the number of stained skin sites, which appeared as blue dots. It has been 
previously shown that the number of stained skin sites visible after microneedle patch 
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insertion is correlated with skin puncture by measuring trans-epidermal water loss [21]. 
Microneedle patches were imaged using brightfield microscopy (SZX12 Olympus, 
Center Valley, PApl990) before and after administration, and the microneedle dimensions 
were measured to calculate the volume dissolved after microneedle patch administration. 
Since placebo microneedle patches (i.e., containing no drug or other active substance) 
were used in this study, it was not possible to assay the microneedle patches for delivery 
efficiency of a drug or active, and therefore this method of usability from staining and 
microscopy was used.  
5.3.6 Survey about microneedle patch administration to measure acceptability 
Participants answered a short questionnaire to solicit information about the 
acceptability of microneedle patches for delivery of drugs or vaccines. We surveyed the 
subjects about pain during microneedle patch application, confidence during self-
administration and subject preferences regarding microneedle patches, conventional 
intramuscular injection and conventional oral delivery using pills.  
Pain during microneedle patch administration was reported by participants using a 
visual analog scale from 0 (no pain) to 10 (worst pain ever). Participants were also asked 
to score their confidence during self-administration of microneedle patches on a score of 
1 to 5 using the following scale: 
1: I’m confident that I applied the patch incorrectly 
2: I’m somewhat confident that I applied the patch incorrectly 
3: I do not know if I applied the patch correctly or incorrectly 
4: I’m somewhat confident that I applied the patch correctly 
5: I’m confident that I applied the patch correctly 
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Subjects were then asked their preferences regarding obtaining medications by 
microneedle patches versus hypodermic needles and microneedle patches versus 
conventional oral delivery by pill.  
5.3.7 Statistical methods 
Statistical analysis was carried out using Prism software version 5 (Graphpad, La 
Jolla, CA). P values < 0.05 were considered significant. Average values of delivery 
efficiency by microscopy were analyzed using a paired t test. 
 
5.4 Results 
5.4.1 Skin tolerability  
We studied skin tolerability of microneedle patch administration to understand the 
local reactions in the skin that occur. These reactions are associated with the patch 
administration process and the patch excipients left in the skin after microneedle 
dissolution. This study did not assess the possible additional effects of delivery of a drug 
or other active to the skin on tolerability. The investigator administered one patch onto 
the subject’s skin and the skin site was monitored, imaged and scored once per day for 7 
days. 
Figure 5.2 shows a series of images from a single representative subject after 
microneedle patch application. Immediately after microneedle patch application at Day 0, 
a rectangular area equal to the patch size exhibited mild erythema with faint redness 
around the rectangle in the area where the adhesive backing was applied to the skin. On 
Day 1, redness from the adhesive backing was fully resolved and the rectangular area 
decreased in redness and size. For the subject in Figure 5.2, all erythema resolved by Day 
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4. There were no other skin conditions or adverse effects noted, and overall the 
microneedle patch was well tolerated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2 Representative images of the site of microneedle patch application on the skin 
over time. Inset shows magnified images of the skin site. Day 0 is immediately after 
patch application and removal. These images are all from the same subject.  
Day 0 
Day 1 Day 2
 
 
Day 1 
Day 4
 
 
Day 1 
Day 3
 
 
Day 1 
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We quantified the skin reactions noted after microneedle patch application over time 
in Figure 5.3. Subjects were asked if they felt pain or tenderness at the skin site. Pain in 
this case was assessed after microneedle patch application was complete, which differs 
from possible pain experienced during microneedle patch insertion, which is addressed in 
the context of the usability analysis. None of the subjects reported pain at the skin site 
after microneedle patch application on Day 0 through Day 7. Only one subject (out of 15) 
reported tenderness at the skin site on Day 0 which was fully resolved by Day 1 and later. 
The tenderness was reported of Grade 1 (i.e., mild discomfort to touch on a scale of 0 to 
4). None of the other subjects reported tenderness at the skin site through Day 7.  
The investigator also scored the skin site for erythema and induration/swelling. 
Erythema was scored based on size and intensity. Based on size, erythema, when present, 
was always of Grade 0.5, which corresponds to a size equal to or less than the patch. As 
noted in Figure 5.3A, erythema was present in 100% of subjects on Day 0 and 80% of 
subjects on Day 1. Erythema continued to subside over time with 33% of subjects having 
erythema on Day 2, 20% of subjects on Day 3 and 13% of subjects on Day 4. By Day 7 
all erythema was fully resolved.  
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Figure 5.3 Skin tolerability after microneedle patch application. Skin sites were 
monitored and scored over a period of one week. (A) Summary of the prevalence of skin 
reactions at different time points. (B) Intensity of erythema in the skin after microneedle 
patch application. Column bars show the percentage of subjects with different grades of 
erythema. None of the subjects had Grade 3 or 4 erythema scores. (C) Representative 
images of skin showing Grade 1 and Grade 2 erythema.  
 
Figure 5.3B charts the score of erythema intensity on a scale of 0 – 4 over time. 
Move to methods Representative examples of Grade 1 and 2 erythema seen in the study 
are shown in Figure 5.3C. On Day 0, 13% (2 out of 15) subjects had very slight erythema 
(Grade 1) while 87% (13 out of 15) subjects had erythema (Grade 2). On Day 1 47% (7 
out of 15) subjects showed Grade 1 erythema and 33% (5 out of 15) subjects showed 
Grade 2 erythema. From Day 2 onwards, erythema, when present, was only Grade 1. 
None of the subjects showed Grade 3 or Grade 4 erythema at any point in the study. In 
addition, none of the subjects showed induration or swelling at the skin site at any time 
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during the study. Overall the patches were tolerated very well in the skin with mild 
transient erythema that resolved fully by Day 7, almost no tenderness and no pain or 
swelling. 
5.4.2 Usability 
We next determined if microneedle patches could be inserted and dissolved in the 
skin in a reliable manner. We also determined if subjects could self-administer 
microneedle patches after only minimal training.  
 Figure 5.4A charts the puncture efficiency as measured by the percentage of 
microneedles in a given patch that inserted into the skin after investigator-administration 
and self-administration. Figure 5.4B shows an example of the subject’s skin stained with 
gentian violet after microneedle patch application. The blue dots show the number of 
sites that were punctured in the skin during microneedle patch application. The mean 
puncture efficiency by skin staining was 99% after investigator-administration and 98% 
after self-administration.  
Figure 5.5 charts the delivery efficiency as measured by the percentage volume of 
microneedles in a given patch that dissolve after patch administration. The mean delivery 
efficiency by microscopy was 74% after investigator-administration and 67% after self-
administration, and the two groups were not statistically different from each other. This 
suggests that overall usability was similar between investigator-administration and self-
administration with minimal training and that microneedle patches can be administered 
reliably.  
 
  
 95 
0
25
50
75
100
Investigator
Administration
Self
Administration
%
 M
ic
ro
n
e
e
d
le
s
 i
n
s
e
rt
e
d
 i
n
 s
k
in
(m
e
a
s
u
re
d
 b
y 
s
k
in
 s
ta
in
in
g
)
 
Figure 5.4 Puncture efficiency of microneedle patch application as determined by the 
percentage of microneedles that inserted into the skin. Skin sites were stained with 
gentian violet dye and the number of dots were counted to measure the number of 
microneedles that punctured into the skin. (A) Puncture efficiency of microneedle patches 
after investigator-administration and self-administration. Column bars represent the 
average percentage of microneedles that inserted into the skin with standard deviation 
error bars shown. (B) Representative magnified image of a stained skin site showing a 10 
x 10 array where the microneedles punctured into the skin.  
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Figure 5.5 Delivery efficiency as determined by the percentage of the volume of 
microneedles that dissolved during microneedle patch application to the skin. 
Microneedle patches were imaged by brightfield microscopy before and after insertion 
into the skin and image analysis was used to determine the volume of microneedles 
dissolved. Volume of microneedles dissolved is interpreted as a measure of the dose 
delivered, i.e., if a drug or vaccine had been incorporated into the microneedles. Each bar 
represents the result from an individual subject. The ‘average’ bars represent the averages 
of the 15 individual bars, with standard deviation error bars shown. 
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B 
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mm 
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5.4.3 Acceptability 
We studied acceptability of microneedle patches by surveying the subjects about 
pain during microneedle patch application, confidence during self-administration and 
subject preferences regarding microneedle patches compared to conventional 
intramuscular injection and conventional oral delivery by pills.  
Figure 5.6A shows the pain score reported by subjects during microneedle patch 
administration. Fourteen out of the 15 subjects reported a pain score of 0 or ‘no pain’ 
during microneedle patch administration. One subject reported a pain score of 1 (on a 
scale of 0 to 10). This indicates that microneedle patch administration was not considered 
painful. 
Figure 5.6B shows the confidence score reported by subjects during self-
administration of microneedle patch. Among the subjects, 53% (8 out of 15) reported that 
they were confident that they applied the microneedle patch correctly (score of 5), and 
33% (5 out of 15) subjects reported that they were somewhat confident that they applied 
the microneedle patch correctly (score of 4). Only 14% (2 out of 15) subjects reported 
that they did not know if they applied the microneedle patch correctly or incorrectly 
(score of 3). None of the subjects reported that they thought that they applied the patch 
incorrectly (score of 1 or 2). Therefore, 85% of the subjects were at least somewhat 
confident that they applied the microneedle patch correctly (confidence score of 4 or 5). 
This shows that the large majority of subjects felt confident self-administering a 
microneedle patch. 
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Figure 5.6 Acceptability survey results from subjects about microneedle patch 
administration. (A) Assessment of pain during microneedle patch administration. Pain 
was scored by subjects on a visual analog scale (VAS) of 0 (No pain) to 10 (Worst pain). 
(B) Confidence of subjects during self-administration of microneedle patches. 
Confidence during self-administration was scored by subjects on a scale of 1 (least 
confident) to 5 (most confident). (C) Preference of subjects for application of 
microneedle patch as compared to intramuscular injection for delivery of medications. 
(D) Preference of subjects for microneedle patch administration as compared to oral 
administration by conventional pill for delivery of medications. 
 
 Figures 5.6C and 5.6D compare the preferences reported by subjects about 
microneedle patches versus conventional delivery methods. Figure 5.6C shows that 93% 
(14 out of 15) of subjects would prefer to obtain their medication by a microneedle patch 
as compared to a conventional intramuscular injection. Only 7% (1 out of 15) of subjects 
reported a preference for intramuscular injection over microneedle patch. That subject 
stated that the longer wear time of the microneedle patch as compared to intramuscular 
injection was the primary reason for preferring intramuscular injection. This suggests that 
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microneedle patches are overwhelmingly preferred over intramuscular injections for 
administration of medications. 
Figure 5.6D shows that 20% (3 out of 15) subjects would prefer a microneedle 
patch over conventional oral delivery by pill for obtaining medication, while another 20% 
reported that they do not care either way. The remaining 60% (9 out of 15) subjects 
reported that they would prefer obtaining their medication by a pill over a microneedle 
patch. This indicates that although oral delivery was preferred, a significant fraction of 
subjects found the microneedle patch to be similar or better than oral administration. 
 
5.5 Discussion 
The goal of the study was to evaluate skin tolerability, usability and acceptability of 
dissolving microneedle patch administration in human subjects to further clinical 
translation of dissolving microneedle patches.  
In this study, microneedle patches were very well tolerated in the skin with mild, 
transient erythema that resolved within 7 days. It is, however, important to note that the 
microneedle patches used in this study were placebos and did not contain any drug or 
vaccine. The presence of drug or vaccine within the microneedle patches could change 
the number or intensity of skin reactions. Tolerability in the skin should also be 
dependent upon the materials used for microneedle patch fabrication and the properties of 
these materials upon dissolution in the skin. Therefore, dissolving microneedle patches 
made of different materials may have different skin tolerability. For example, Hirobe S. 
et al reported significantly greater erythema associated with application of dissolving 
microneedle patches containing influenza vaccine to human subjects [16]. 
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This study also showed that 98% – 99% of microneedles in a given patch punctured 
the skin’s surface based on data from skin staining, which leaves little room for 
improvement. Based on microscopy analysis about 70% of the volume of microneedles 
was dissolved after microneedle patch administration. The amount of dissolution should 
depend on microneedle patch geometry, the materials that comprise the microneedle 
patch, the force of microneedle patch application and other factors. Further optimization 
of these factors could lead to greater delivery efficiency. 
For most subjects, investigator-administration and self-administration delivery 
efficiencies were similar to each other with no statistically significant difference. 
However, there were certain subjects (e.g., subjects 5 and 13 where self-administration 
delivery was much lower than investigator-administration. That being said, there were 
also subjects for whom self-administration yielded more efficient delivery than 
investigator-administration. Future studies should expand upon these proof-of-concept 
results to assess self-administration protocols in larger populations and using microneedle 
designs that are further optimized for simple, reliable administration with less variability. 
Microneedle patches were well accepted in this study with minimal pain of insertion 
and were overwhelmingly preferred over intramuscular injection. This is consistent with 
previous studies reporting less pain from microneedle administration compared to 
injection [21-23] and reporting overall preference of microneedle patches over drug or 
vaccine delivery by injection [22, 24].  
The large majority of participants were at least somewhat confident that they self-
administered the microneedle patch correctly, and none reported that they thought they 
had applied the patch incorrectly. Almost all participants preferred microneedle patch 
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administration to intramuscular injection and some preferred the patch to oral 
administration. This indicates that offering microneedle patch administration for 
medications that otherwise require injection could be a strategy to increase patient 
compliance with these therapies.  
 
5.6 Conclusions 
This study evaluated skin tolerability, usability and acceptability of dissolving 
microneedle patch administration in humans. The microneedle patches were very well 
tolerated in the skin with minimal erythema that resolved fully within seven days and 
caused no pain or swelling. Microneedle patches were administered reliably by hand 
without the need of an applicator and delivery efficiencies were similar between 
investigator-administration and self-administration. Microneedle patch administration 
was not painful and the large majority of subjects were at least somewhat confident that 
they self-administered the patch correctly. Microneedle patch administration was 
overwhelmingly preferred over conventional needle and syringe injection for delivery of 
medications. 
Altogether the results of this study show the feasibility of using dissolving 
microneedle patches for investigator-administration as well as self-administration for 
future applications in drug and vaccine delivery in a well-tolerated and reliable manner 
that offers an attractive alternative to conventional hypodermic needles. 
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CHAPTER 6 
CONCLUSIONS 
 
The goal of this study was to develop dissolving microneedle patches to further their 
clinical translation in the context of vaccination in developing countries. This thesis 
evaluated rabies vaccination in dogs with a microneedle patch and the tolerability, 
usability and acceptability of placebo dissolving microneedle patches in human subjects. 
The key conclusions from these studies are listed below: 
 
6.1 Rabies vaccination in dogs using a microneedle patch 
We have shown for the first time that dissolving microneedle patches can safely and 
effectively administer rabies DNA vaccine to dogs using a delivery technology that is 
easy to administer and may enable cost savings.  
 The vaccine was stable upon formulation and storage for at least 3 weeks at 4 °C in a 
microneedle patch.  
 The patches were administered manually to dog ears by pressing with the thumb, 
without the need of an applicator, and the microneedles dissolved in the skin within 
15 min, thereby leaving no sharps waste.  
 Microneedle patches were well tolerated in the skin with mild erythema, minimal 
wheal formation and complete resolution of skin reactions within 7 days, and 
generated no systemic adverse events. 
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 Microneedle patches were at least as immunogenic as intramuscular injection at the 
same dose, as demonstrated by similar serum neutralizing antibody titers.  
 A ten-fold lower vaccine dose administered by microneedle patch generated a weaker 
immune response compared to full-dose intramuscular vaccination. 
In contrast to traditional needle-and-syringe vaccination, these microneedle 
patches were designed to enable administration by minimally trained personnel, increase 
safety by generating no sharps waste and utilize a DNA vaccine that is relatively 
inexpensive to manufacture compared to traditional human vaccines, all of which are 
expected to enable increased vaccination coverage at reduced cost. For these reasons, 
dissolving microneedle patches may serve as an innovative and effective approach to 
mass vaccinate dogs and humans. This first study on veterinary applications for 
microneedle patches should motivate further research in this field. 
 
6.2 Tolerability, usability and acceptability of dissolving microneedle patch 
administration in human subjects 
6.2.1 Tolerability 
 Dissolving microneedle patches were very well tolerated in the skin with minimal 
erythema that resolved fully within seven days.  
 Based on size, erythema when present was always of Grade 0.5, i.e., size equal to or 
less than the microneedle patch.  
 Based on intensity, on Day 0, 13% (2 out of 15) subjects had Grade 1 erythema while 
87% (13 out of 15) subjects had Grade 2 erythema. On Day 1, 47% (7 out of 15) 
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subjects showed Grade 1 erythema and 33% (5 out of 15) subjects showed Grade 2 
erythema. From Day 2 onwards, erythema, when present in subjects, was only Grade 
1 erythema. None of the subjects showed Grade 3 or Grade 4 erythema at any point in 
the study. 
 There was no induration or swelling noted at the skin site on any of the days through 
Day 7.  
 Only 6.7% (1 out of 15) of subjects reported tenderness at the skin site on Day 0 after 
microneedle patch administration that resolved by Day 1. The tenderness was 
reported of Grade 1 or mild discomfort to touch on a scale of 0 to 4. None of the other 
subjects reported any tenderness at the skin site through Day 7. 
 There was no pain reported at the skin site on any of the days through Day 7.  
6.2.2 Usability 
 Microneedle patches were mechanically strong enough to insert into skin as assessed 
by gentian violet staining. Mean puncture efficiencies were 99% for investigator-
administration and 98% for self-administration. 
 The mean delivery efficiency assessed by microscopic examination of microneedle 
dissolution in the skin was 74% for investigator-administration and 67% for self-
administration, and the two groups were not statistically different from each other. 
Thus overall usability was similar between investigator-administration and self-
administration. 
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6.2.3 Acceptability 
 Microneedle patch administration was not considered painful. Fourteen out of the 15 
subjects reported a pain score of 0 or ‘no pain’ during microneedle patch 
administration. 1 subject reported a pain score of 1 (on a scale of 0 to 10). 
 85% of the subjects were at least somewhat confident that they applied the 
microneedle patch correctly (confidence score of 4 or 5). 
 93% (14 out of 15) subjects would prefer to obtain their medication by a microneedle 
patch as compared to a conventional intramuscular injection. 
 20% (3 out of 15) subjects would prefer a microneedle patch over conventional oral 
delivery by pill for obtaining medication, while another 20% reported that they do not 
care either way. 60% (9 out of 15) subjects reported that they would prefer obtaining 
their medication by a pill over a microneedle patch. 
We have shown that dissolving microneedle patches can be administered reliably 
by a simple administration process without the need of an applicator, the microneedles 
are safe after insertion and dissolution in the skin and overwhelmingly preferred over 
intramuscular injection. The results of this study show the feasibility of using dissolving 
microneedle patches for investigator-administration as well as self-administration of drug 
or vaccines in a safe and reliable manner and offer an attractive alternative to 
conventional hypodermic needles. This study should motivate further studies on clinical 
translation of microneedles. 
The results of this thesis have shown positive data for rabies vaccination of dogs 
as well as positive data for clinical use of microneedle patches. Altogether, these results 
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should further clinical translation of dissolving microneedle patches for vaccination in 
developing countries. 
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CHAPTER 7 
FUTURE DIRECTIONS 
 
7.1 Improving rabies vaccination in dogs using a microneedle patch 
 Stability: The study showed that the DNA vaccine was stable upon formulation and 
storage for at least 3 weeks at 4 °C in a microneedle patch. However, we did not test 
long term stability or stability at elevated temperatures. Future work can address 
stability of DNA vaccine within the microneedle patch at 40°C over a period of 
months. Eliminating the cold chain during storage will be a big step towards 
vaccination in developing countries. It will also be important to characterize 
mechanical strength and insertion ability of microneedle patches after long term 
storage at elevated temperatures. Microneedle patches were stored in a foil pouch 
with desiccant until their time of use and this study did not evaluate the effect of 
humidity on the mechanical strength of microneedles. Since microneedles were made 
of highly water soluble excipients, it is possible that they may absorb moisture from 
the air and become soft before insertion into skin. Future work can address the rate at 
which this occurs and how soon after opening the foil pouch will the microneedle 
patches be suitable for use.  
 Administration of microneedle patches: The patches were administered manually to 
dog ears by pressing with the thumb without an applicator and the microneedles 
dissolved in the skin within 15 minutes. While the 15 minutes wear time was used for 
this first proof of concept study, it would not be viable during vaccination of dogs in 
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developing countries. Future work can address development of fast dissolving 
microneedle patches that can dissolve fully within 1 to 2 minutes.  
 Immunogenicity: Microneedle patches were as immunogenic as intramuscular 
injection at the same dose, but a 10-fold lower microneedle patch dose resulted in a 
lower immune response than full dose intramuscular injection. Future work can 
address if microneedle patches can enable dose sparing at doses lower than 10-fold. 
Future work should also address longevity of immune response and a challenge in 
dogs with rabies virus to test survival after vaccination.  
` 
7.2 Tolerability, usability and acceptability of dissolving microneedle patch 
administration in human subjects 
 Tolerability: Dissolving microneedle patches were well tolerated in the skin with 
minimal erythema that resolved within 7 days. However, no drug or vaccine was used 
in this study. Future studies should address skin tolerability with the presence of an 
active, as this may be different from placebo microneedle patches. 
 Usability: Puncture efficiencies were over 95% for investigator-administration and 
self-administration and delivery efficiencies were around 70%. Future work can 
address improving the delivery efficiencies further by optimizing the microneedle 
geometry, excipients used in microneedle fabrication as well as optimizing the force 
feedback indicator and developing a more robust administration protocol. 
 Acceptability: Dissolving microneedle patch administration was not painful and was 
overwhelmingly preferred over intramuscular injection. Future work can address 
studying acceptability in a larger diverse group to get further insights into people’s 
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preferences for microneedle patches and self-administration. Future work should also 
address quick dissolving microneedles to further improve acceptability. 
 
7.3 Recommendations for microneedle patches 
 Quick dissolving: Future work should address development of dissolving 
microneedle patches that can dissolve and deliver drugs or vaccines within 1 
minute. It should also be noted to test the mechanical strength of these 
microneedles when exposed to short periods of humidity outside of storage 
packaging. 
 Limiting vaccine wastage: Future manufacturing processes for microneedle 
patches should focus on minimizing the wastage of vaccine used for production of 
microneedle patches. 
 Identification of terminal sterilization methods: For clinical translation and large 
scale manufacturing, identification of terminal sterilization methods for 
microneedle patches could greatly reduce the costs associated with low-bioburden 
or aseptic manufacturing. 
 Evaluating self-administration in larger groups: Future work should evaluate self-
administration in larger groups to get a better sense for people’s preferences 
towards self-administration. Policy implications of self-administration also need 
to be studied. 
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Overall, dissolving microneedle patches have a great potential to improve vaccination 
in developing countries and continued efforts in these areas can help realize their 
potential.  
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APPENDIX A 
SUPPLEMENTARY INFORMATION FOR CHAPTER 5  
 
Table A.1 Skin tolerability scoring scale to evaluate local reactions in the skin. 
 
 
114 
APPENDIX B 
INACTIVATED POLIO VACCINE FORMULATION IN 
MICRONEEDLE PATCHES 
 
The overall goal was to study formulations to stabilize Inactivated Polio Vaccine (IPV) in 
a dry state in a microneedle patch and test immunogenicity in rats. We have presented 
some preliminary data that can guide further development of an inactivated polio vaccine 
microneedle patch. These studies were performed as a component of a much larger 
project involving multiple researchers. These studies provide a look into some of the 
early work done on this project that helped shape it subsequent direction and successes.  
B.1 IPV stabilization in microneedle patches with Human Serum Albumin 
Based on an excipient screen by drying vaccine on PDMS surface, maltodextrin 
13 and Human Serum Albumin (HSA) were identified as suitable excipients for IPV 
stabilization upon drying (data not shown). Dissolving microneedle patches were 
fabricated using these excipients and tested in Wistar rats for immunogenicity.  
Neutralizing antibody titers specific to each serotype were measured in the serum to 
determine immunogenicity. 
Figure B.1 shows the antibody titers at week 4 after vaccination. For IPV type 1, 
dissolving microneedle patches at 100%, 200% and 400% of the human dose were not 
immunogenic as compared to the intramuscular injection at 100%. Microneedle patches 
were reconstituted in phosphate-buffered saline and injected intramuscularly at 100% 
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human dose (labeled as “IM of MN 100%” in Figure B.1), but were not immunogenic. 
This suggests that the vaccine activity as measured by ELISA in the reconstituted 
microneedle patch solution was not correlative with immunogenicity in the rat model. 
Intradermal injection at 20% of the human dose was inferior in immune response to 
intramuscular injection at 20%. Similar trends were noted for IPV types 2 and 3.  In a 
follow-up study, microneedle patches were fabricated without HSA in the formulation 
and the reconstitutions of microneedle patches were found to be immunogenic (data not 
shown). Our hypothesis was that HSA interferes with immune response in the rats after 
drying (and reconstitution) with IPV. 
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Figure B.1 Antibody titers after vaccination of rats using IPV microneedle patch 
containing HSA. Individual data point represent data from an individual rat. The red lines 
represent the median values.  
 
B.2 IPV stabilization in microneedle patches using sorbitol, magnesium chloride and 
monosodium glutamate  
Based on a previously published study on stabilization of IPV after lyophilization 
[1], we wanted to evaluate the suitability of sorbitol, magnesium chloride and 
monosodium glutamate for IPV stabilization in microneedle patches. Microneedle patch 
fabrication differs from the lyophilization drying process used to originally identify this 
formulation. In our study, the vaccine was concentrated and buffer-exchanged into 
McIlvaine buffer (phosphate-citrate buffer) using a spin-filter before microneedle 
fabrication. Microneedle fabrication was modeled using a first cast – casting onto a 
PDMS chip (to simulate a PDMS microneedle mold) with vaccine and stabilizing 
excipients (i.e., sorbitol, magnesium chloride and monosodium glutamate) followed by 
air drying. A second cast was applied using a polymer solution (20% PVA, 20% sucrose) 
followed by air drying. Finally, we made actual microneedle patches using these two 
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casting steps but with microneedle molds rather than chips. Our goal was to evaluate the 
stability of the vaccine after each of these steps by measuring activity by ELISA and 
injecting the solutions into rats for testing immunogenicity. No microneedle patches were 
applied to the rats  
Figure B.2 shows the antibody titers after vaccination in rats at 4 weeks. For all 
three serotypes, similar titers are noted across all the groups, suggesting that no vaccine 
activity was lost after each additional fabrication step. 
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Figure B.2 Antibody titers after vaccination of rats with intramuscular injections of 
formulations at different stages of microneedle patch fabrication. Individual data point 
represent data from an individual rat. The red lines represent the median values. 
As a next step, we fabricated microneedle patches using this formulation and 
administered them to Wistar rats to test immunogenicity of microneedle patches 
containing IPV. Figure B.3 shows the antibody titers for IPV Type 1 and Type 2 were 
equivalent between the positive control of intramuscular injection of liquid vaccine and 
intramuscular injection of a reconstituted microneedle patch, which was consistent with 
the previous study. For Type 3, antibody titers for the reconstituted microneedle patch 
were slightly lower than the positive control, suggesting that some loss may have 
occurred during microneedle patch fabrication. For all the serotypes, the microneedle 
patch administered to the rat generated lower antibodies than the intramuscular injection 
control. We hypothesized this was due to inefficient delivery from microneedle patches.  
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Figure B.3 Antibody titers after vaccination of rats using IPV microneedle patch. 
Individual data point represent data from an individual rat. The red lines represent the 
median values. 
Upon further inspection of microneedle patches fabricated for the study, we noted 
that the sharp tips of the microneedles were broken during fabrication, which would make 
penetrating the skin difficult and greatly reduce vaccine delivery to the skin (Figure B.4). 
We believe this is the reason why the microneedle patches provided poor 
immunogenicity in this study. Additional studies are needed to further assess the stability 
of this formulation.  
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Figure B.4 IPV microneedle patch showing tips that are not sharp due breakage during 
microneedle patch fabrication.  
  
1. Kraan, H., P. van Herpen, G. Kersten, and J.P. Amorij, Development of 
Thermostable Lyophilized Inactivated Polio Vaccine. Pharm Res, 2014. 
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APPENDIX C 
DESIGN, DEVELOPMENT AND FABRICATION OF 
MICRONEEDLE PATCHES 
 
To support translation of microneedle patches from pre-clinical development into 
clinical trials, this thesis has examined the effect of microneedle patch application to local 
skin reactions, reliability of use and acceptability to patients. This appendix outlines the 
studies that helped guide the development of the placebo dissolving microneedle patch 
used in the study. Microneedle patches contain a force feedback indicator (FFI) device 
incorporated within them, such that when pressing down on the microneedles with the 
thumb, the FFI produces a click sound to indicate that enough force has been applied. 
The patch is then left on the skin for 20 minutes for dissolution of microneedles and then 
peeled away. The following studies provide background information and preliminary 
results on how the FFI and the microneedle patch insertion protocol were developed. 
C.1 Optimization of insertion force using the FFI 
Previous results with insertion of stainless steel metal microneedle patches in 
human subjects reported that an insertion force of 37 N was sufficient for microneedles to 
puncture the skin, as noted by gentian violet skin staining [1].  We used this force as a 
starting range for insertion of dissolving microneedle patches. Dissolving microneedles 
have less mechanical strength than metal microneedles and the tips of dissolving 
microneedles are less sharp than metal microneedles. For these reasons, it was 
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hypothesized that the force of insertion of dissolving microneedles could be higher than 
the reported force for metal microneedles.  
We tested FFIs with two forces 8 lbf (35 N) and 13 lbf (57 N). The investigator 
applied the microneedle patch with these two FFIs to the same subject, while keeping all 
other aspects of the insertion protocol similar. The microneedles were imaged after 
insertion into the skin. Figure C.1 shows representative images of the microneedle patch 
from this study. Based on these studies it was noted that more uniform and complete 
dissolution was observed in the higher force 13 lbf FFI. It was not significantly more 
difficult to apply this force with the thumb as compared to the lower force FFI and it was 
determined that the 13 lbf FFI would be an appropriate choice for the insertion of 
microneedle patch. 
 
A 
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Figure C.1 Representative images of microneedles (A) Before insertion (B) After 
insertion with 8 lbf FFI and (C) After insertion with 13 lbf FFI. 
 
C.2 Optimization of number of clicks using the FFI  
 We wanted to study the effect of number of clicks using the FFI and the delivery 
efficiency of microneedles. The FFI produces a click sound when sufficient force has 
been applied. We studied the effect of applying the force once (one click sound) or 
applying the force five consecutive times (five click sounds) on microneedle delivery 
efficiency in pig skin in-vitro.  
B 
C
C 
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 Figure C.2 shows the volume of microneedle dissolved between one click and 
five clicks. Two investigators, A and B, applied three microneedle patches each by one 
click and five clicks (A 5x and B 5x) to pig skin in-vitro. As seen in the figure, no 
significant difference is seen between groups A and A 5x, B and B 5x, and there is 
minimal variation between the two investigators. Based on these results, only a one click 
insertion was determined to be necessary for the microneedle patch insertion process. 
 
 
 
 
 
 
 
 
 
Figure C.2 Volume of microneedle dissolved and representative images of microneedles 
between one click and five clicks.  
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C.3 Optimization of microneedle patch wear time  
While preliminary information on microneedle patch dissolution pig skin in-vitro, 
limited information was available on microneedle patch dissolution time in human 
subjects. We wanted to test the effect of patch wear time on microneedle dissolution in 
human subjects. An earlier formulation of dissolving microneedle patches consisted of 
gelatin and sucrose and was tested in human subjects with a patch wear time ranging 
from 30 seconds to 15 minutes. 
Figure C.3 shows the representative images of microneedle patches from the time 
course study in human subjects. The pink border marks the size of the microneedle at 
different time points. It can be seen that at 2 minutes more than half of the microneedle 
length is dissolved in the skin, at 5 to 10 minutes most of the microneedle length is 
dissolved in the skin. It is important to note that the microneedles sit on top a pedestal 
base that does not contain any vaccine and only provides a mechanical function. 
Therefore, a patch wear time of 10 minutes was considered suitable for microneedles 
with the gelatin and sucrose formulation. 
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Figure C.3. Representative images of microneedles before insertion into human subjects 
and at different time points after insertion and dissolution into the skin.  
As a next step, a similar study was carried out with the polyvinyl alcohol and 
sucrose formulation studied in Chapter 5 and a patch wear time of 20 minutes was found 
to be optimal (data not shown) and chosen as the patch wear time for the human study.  
  
1. Norman, J.J., J.M. Arya, M.A. McClain, P.M. Frew, M.I. Meltzer, and M.R. 
Prausnitz, Microneedle patches: usability and acceptability for self-vaccination 
against influenza. Vaccine, 2014. 32(16): p. 1856-62. 
 
